

Table 2.9  
All Cancer Sites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	69.2	70.7	73.2	76.4	76.6	77.0	77.7	78.0	78.7	79.0	79.5	79.8	79.5	80.1	80.3	80.9	81.4	81.6	81.8	81.7	81.9	81.6
2-year	59.8	61.3	64.5	68.8	69.3	70.2	70.9	71.4	72.2	72.7	73.4	73.9	73.4	74.0	74.3	75.3	75.7	75.8	75.9	76.0	76.1	
3-year	54.7	56.2	59.8	64.9	65.7	66.7	67.4	68.0	68.9	69.5	70.2	70.8	70.3	70.9	71.2	72.2	72.6	72.8	72.8			
4-year	51.4	52.8	56.7	62.3	63.3	64.3	65.1	65.7	66.8	67.4	68.2	68.8	68.2	68.7	69.2	70.1	70.6	70.5	70.7			
5-year	48.9	50.2	54.4	60.4	61.6	62.5	63.3	64.0	65.2	66.0	66.8	67.2	66.7	67.3	67.6	68.6	69.1	68.9				
6-year	47.0	48.2	52.6	58.9	60.2	61.2	61.9	62.7	63.9	64.8	65.6	66.1	65.4	66.0	66.4	67.5	67.9					
7-year	45.4	46.5	51.0	57.5	59.0	60.1	60.9	61.6	62.9	63.7	64.6	65.1	64.4	65.0	65.4	66.5						
8-year	44.1	45.1	49.8	56.4	58.0	59.1	60.0	60.8	61.9	62.6	63.7	64.2	63.5	64.2	64.5							
9-year	42.9	43.9	48.6	55.4	57.2	58.2	59.1	59.8	61.1	61.9	63.0	63.5	62.7	63.3								
10-year	41.8	42.8	47.6	54.5	56.4	57.4	58.4	59.0	60.4	61.2	62.3	62.9	61.8									
11-year	40.8	41.9	46.8	53.7	55.6	56.7	57.7	58.3	59.7	60.4	61.6	62.2										
12-year	40.0	41.0	45.9	52.9	54.8	56.1	57.1	57.7	59.0	59.7	60.9											
13-year	39.3	40.3	45.1	52.3	53.9	55.4	56.4	57.0	58.4	59.0												
14-year	38.7	39.6	44.4	51.6	53.2	54.8	55.8	56.4	57.7													
15-year	38.0	38.9	43.7	51.0	52.6	54.2	55.2	55.9														
16-year	37.4	38.2	43.1	50.4	52.0	53.6	54.5															
17-year	36.8	37.6	42.6	49.7	51.3	53.0																
18-year	36.3	37.1	42.1	49.1	50.7																	
19-year	35.9	36.5	41.7	48.5																		
20-year	35.5	36.0	41.2																			
21-year	35.0	35.5	40.8																			
22-year	34.5	35.1	40.3																			
23-year	34.1	34.6	39.8																			
24-year	33.6	34.2	39.3																			
25-year	33.1	33.8																				
26-year	32.7	33.4																				
27-year	32.4	33.0																				
28-year	32.0	32.6																				
29-year	31.7	32.2																				
30-year	31.3																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 2.10  
All Cancer Sites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	63.7	66.6	69.9	75.5	75.3	76.2	76.9	76.8	78.0	78.6	79.1	79.2	79.0	79.7	80.0	80.9	81.4	81.3	81.5	81.3	81.2	80.2
2-year	53.4	56.4	60.4	67.7	68.0	69.4	70.2	70.3	71.5	72.5	73.0	73.5	73.0	73.9	74.1	75.4	75.9	75.5	75.5	75.6	75.4	
3-year	48.2	51.2	55.5	64.0	64.6	66.1	67.0	67.1	68.5	69.5	70.3	70.8	70.1	71.0	71.2	72.5	73.1	72.6	72.7	72.7		
4-year	44.7	47.7	52.2	61.6	62.4	63.8	64.9	65.0	66.6	67.6	68.4	69.1	68.3	69.2	69.4	70.6	71.3	70.6	70.8			
5-year	42.2	45.0	49.9	59.8	60.8	62.3	63.1	63.5	65.2	66.2	67.3	67.9	67.1	68.0	68.1	69.4	70.1	69.4				
6-year	40.2	43.0	48.1	58.4	59.5	61.1	61.8	62.2	64.0	65.1	66.3	66.9	66.0	66.9	66.9	68.5	69.0					
7-year	38.5	41.3	46.4	57.0	58.5	60.0	61.0	61.2	63.2	64.2	65.5	66.2	65.1	65.9	66.0	67.6						
8-year	37.1	39.8	45.0	55.9	57.6	59.2	60.2	60.5	62.3	63.2	64.8	65.4	64.3	65.1	65.1							
9-year	35.8	38.6	43.8	54.8	56.8	58.4	59.4	59.6	61.6	62.6	64.3	64.8	63.4	64.4								
10-year	34.6	37.5	42.8	53.9	55.9	57.5	58.8	58.9	60.9	61.9	63.5	64.3	62.6									
11-year	33.5	36.5	41.8	53.1	55.2	56.8	58.1	58.2	60.4	60.9	62.9	63.5										
12-year	32.6	35.6	40.9	52.3	54.3	56.1	57.5	57.4	59.7	60.4	62.4											
13-year	31.8	34.9	40.0	51.6	53.4	55.6	56.7	56.8	59.1	59.7												
14-year	31.1	34.1	39.3	50.9	52.5	55.0	56.0	56.3	58.5													
15-year	30.3	33.4	38.5	50.2	51.8	54.4	55.6	56.0														
16-year	29.7	32.6	37.8	49.6	51.2	53.8	54.8															
17-year	29.0	32.0	37.3	48.9	50.6	53.3																
18-year	28.4	31.4	36.7	48.4	50.2																	
19-year	28.0	30.8	36.2	47.7																		
20-year	27.5	30.3	35.8																			
21-year	27.0	29.8	35.4																			
22-year	26.5	29.3	34.9																			
23-year	26.1	28.8	34.4																			
24-year	25.5	28.4	33.9																			
25-year	25.0	28.0																				
26-year	24.5	27.5																				
27-year	24.2	27.2																				
28-year	23.8	26.9																				
29-year	23.5	26.6																				
30-year	23.1																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 2.11  
All Cancer Sites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	74.6	74.9	76.7	77.5	77.9	77.9	78.6	79.3	79.4	79.5	80.0	80.4	80.0	80.4	80.7	80.9	81.3	81.9	82.2	82.2	82.6	83.0
2-year	66.0	66.2	68.7	70.0	70.7	71.0	71.6	72.5	73.0	73.0	73.8	74.4	73.9	74.2	74.6	75.1	75.5	76.1	76.4	76.4	76.8	
3-year	61.2	61.2	64.2	65.9	66.9	67.3	67.9	69.0	69.4	69.6	70.2	70.8	70.4	70.8	71.2	71.8	72.0	72.5	72.9	72.9		
4-year	57.9	57.9	61.3	63.2	64.3	64.7	65.3	66.5	67.1	67.3	68.0	68.4	68.1	68.3	69.0	69.5	69.8	70.3	70.6			
5-year	55.6	55.3	59.0	61.1	62.4	62.8	63.5	64.6	65.2	65.7	66.2	66.6	66.2	66.6	67.2	67.7	68.1	68.3				
6-year	53.6	53.4	57.3	59.5	60.9	61.3	62.0	63.2	63.7	64.4	64.9	65.2	64.9	65.2	65.9	66.4	66.7					
7-year	52.1	51.7	55.7	58.1	59.6	60.2	60.9	62.1	62.6	63.2	63.6	64.0	63.7	64.1	64.8	65.3						
8-year	50.8	50.3	54.5	57.1	58.6	59.1	59.9	61.1	61.5	62.1	62.6	63.0	62.7	63.1	63.9							
9-year	49.7	49.2	53.5	56.1	57.6	58.1	58.9	60.1	60.7	61.3	61.7	62.1	61.9	62.2								
10-year	48.7	48.1	52.5	55.2	56.9	57.3	58.1	59.2	60.0	60.5	60.9	61.5	60.9									
11-year	47.8	47.1	51.6	54.4	56.0	56.7	57.3	58.5	59.0	59.7	60.2	60.8										
12-year	47.0	46.3	50.8	53.6	55.3	56.1	56.8	58.0	58.4	59.0	59.3											
13-year	46.4	45.6	50.1	53.0	54.4	55.3	56.2	57.2	57.7	58.3												
14-year	45.7	44.9	49.4	52.3	53.9	54.6	55.6	56.5	56.9													
15-year	45.1	44.3	48.8	51.8	53.4	54.0	55.0	55.8														
16-year	44.6	43.6	48.2	51.2	52.7	53.4	54.1															
17-year	44.0	43.0	47.7	50.6	52.1	52.7																
18-year	43.6	42.5	47.3	50.0	51.3																	
19-year	43.2	41.9	46.8	49.4																		
20-year	42.7	41.5	46.3																			
21-year	42.1	40.9	45.9																			
22-year	41.7	40.5	45.4																			
23-year	41.3	40.0	45.0																			
24-year	40.8	39.5	44.5																			
25-year	40.3	39.1																				
26-year	39.9	38.7																				
27-year	39.5	38.2																				
28-year	39.2	37.8																				
29-year	38.8	37.4																				
30-year	38.4																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 3.9  
Cancer of the Brain and Other Nervous System (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	46.3	47.4	50.9	52.7	52.3	53.3	51.4	54.1	55.0	55.6	57.3	59.3	56.9	57.2	58.5	61.7	61.7	62.3	62.5	61.6	60.6	62.6
2-year	32.3	33.8	36.8	38.8	39.1	40.7	38.0	40.7	40.2	41.7	42.3	46.4	43.3	43.1	45.7	47.0	47.2	46.5	46.7	46.3	44.2	
3-year	27.9	29.4	32.6	34.9	36.1	36.6	34.1	35.6	35.9	38.2	38.9	40.3	38.0	38.2	39.8	40.4	40.7	40.8	41.1	39.2		
4-year	25.1	26.5	29.9	32.5	34.4	34.5	31.8	32.8	33.6	36.0	36.6	38.0	35.8	36.0	37.0	37.9	37.2	37.3	37.7			
5-year	23.1	24.6	27.9	30.7	33.3	32.5	30.2	30.9	32.2	34.7	34.6	35.8	33.9	35.0	34.7	35.6	35.1	35.7				
6-year	21.4	23.1	26.5	29.5	32.3	31.2	28.1	29.6	30.7	33.2	33.6	34.2	32.7	33.5	32.6	33.8	33.1					
7-year	20.4	21.9	25.4	28.2	31.3	30.3	27.4	28.5	29.9	31.6	32.3	33.3	31.1	32.0	31.6	33.0						
8-year	19.4	20.8	24.1	27.4	30.5	28.8	26.6	27.6	29.2	30.8	31.4	32.4	30.1	31.0	30.2							
9-year	18.4	19.8	23.3	26.5	29.9	27.7	25.6	27.0	28.1	29.9	30.8	31.4	29.3	30.1								
10-year	17.7	18.8	22.5	25.8	28.9	27.1	24.4	26.2	27.6	29.1	30.3	30.5	28.9									
11-year	17.1	18.1	21.9	25.2	28.1	26.1	23.8	25.6	26.7	28.1	29.4	29.6										
12-year	16.6	17.6	21.3	24.5	27.8	25.1	23.0	24.9	25.9	27.2	28.6											
13-year	16.2	16.9	20.8	24.1	26.6	24.7	22.7	24.2	25.4	26.5												
14-year	15.8	16.5	20.1	23.4	25.9	24.4	22.4	23.5	24.9													
15-year	15.3	16.0	19.5	22.8	25.3	23.9	22.4	22.2														
16-year	15.0	15.5	19.2	22.4	24.2	23.2	21.5															
17-year	14.6	15.2	18.7	21.9	23.9	23.1																
18-year	14.4	14.8	18.2	21.4	23.8																	
19-year	14.0	14.3	17.7	21.1																		
20-year	13.7	13.9	17.5																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 3.10  
Cancer of the Brain and Other Nervous System (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	45.8	48.4	51.0	54.5	54.5	54.5	54.4	54.2	55.0	54.2	55.1	59.0	57.0	59.3	57.8	63.8	61.6	62.7	63.8	63.2	61.7	63.0
2-year	31.3	33.5	36.1	39.6	40.3	39.7	39.5	39.8	38.8	39.6	38.5	46.1	41.8	44.5	44.7	46.9	45.5	45.8	45.8	46.9	43.9	
3-year	26.4	29.3	31.5	35.3	37.2	35.8	34.9	35.1	34.1	35.8	35.2	39.1	36.1	39.4	39.0	39.5	39.0	40.0	40.8	39.0		
4-year	23.9	25.9	28.5	33.0	35.9	33.6	32.5	31.7	31.5	33.3	32.5	36.2	34.2	36.7	36.4	36.6	34.3	35.3	36.6			
5-year	21.5	23.6	26.3	31.1	34.8	31.2	30.4	29.9	29.9	32.1	30.8	33.4	32.9	35.8	34.2	35.1	32.9	33.8				
6-year	20.0	22.2	24.9	29.9	33.4	29.6	28.1	27.9	28.4	30.7	29.8	31.4	31.5	34.4	31.5	33.2	30.7					
7-year	18.9	21.1	23.7	28.5	32.1	28.7	27.1	26.8	27.8	28.5	28.6	30.4	29.7	32.7	30.0	32.3						
8-year	17.8	20.2	22.5	27.8	30.9	27.1	26.5	26.0	26.9	27.7	27.6	29.5	28.5	31.3	28.5							
9-year	16.9	19.0	21.9	26.8	30.1	26.0	25.8	25.1	25.3	26.7	27.2	28.5	28.0	30.2								
10-year	16.3	18.0	21.0	26.1	29.1	25.5	24.7	24.5	24.5	25.7	27.1	27.8	27.5									
11-year	15.5	17.4	20.5	25.3	28.3	24.7	24.3	23.6	23.1	24.8	26.1	26.5										
12-year	14.9	16.9	20.0	24.7	27.9	23.5	23.1	22.8	22.5	23.9	25.0											
13-year	14.5	16.3	19.5	24.3	26.4	23.2	22.9	22.5	22.3	23.7												
14-year	14.4	15.8	18.9	23.5	25.5	23.0	22.6	21.9	21.8													
15-year	13.9	15.3	18.3	22.8	24.8	22.6	22.6	20.8														
16-year	13.8	14.8	18.0	22.4	23.0	21.8	22.1															
17-year	13.5	14.4	17.6	21.9	22.7	21.5																
18-year	13.2	14.1	17.1	21.5	22.5																	
19-year	12.8	13.6	16.6	21.3																		
20-year	12.6	13.3	16.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 3.11  
Cancer of the Brain and Other Nervous System (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	47.0	46.2	50.7	50.4	49.5	51.7	47.6	53.9	55.0	57.3	60.2	59.6	56.9	54.6	59.2	58.8	61.9	61.9	60.9	59.7	59.4	62.2
2-year	33.5	34.1	37.8	37.8	37.6	42.0	36.2	41.7	42.1	44.4	47.2	46.7	45.2	41.2	46.8	47.2	49.3	47.3	47.7	45.5	44.6	
3-year	29.8	29.5	34.0	34.3	34.5	37.8	33.0	36.1	38.1	41.3	43.5	41.9	40.2	36.8	40.8	41.6	42.8	41.7	41.5	39.5		
4-year	26.7	27.3	31.7	31.8	32.3	35.7	30.8	34.0	36.3	39.4	42.0	40.1	37.7	35.1	37.7	39.7	40.8	39.8	39.1			
5-year	25.1	25.9	30.0	30.3	31.4	34.1	29.8	32.1	35.2	38.0	39.4	38.8	35.1	34.1	35.2	36.2	37.9	38.0				
6-year	23.3	24.2	28.5	29.0	30.8	33.2	28.2	31.4	33.6	36.4	38.5	37.5	34.0	32.4	34.0	34.7	36.1					
7-year	22.3	22.8	27.5	27.8	30.2	32.3	27.9	30.5	32.6	35.5	37.1	36.9	32.7	31.1	33.5	33.8						
8-year	21.3	21.7	26.1	26.9	29.8	31.1	26.7	29.5	32.1	34.7	36.3	35.9	32.0	30.6	32.2							
9-year	20.3	20.9	25.1	26.1	29.7	29.9	25.3	29.1	31.8	33.9	35.5	34.8	30.8	29.9								
10-year	19.6	19.9	24.4	25.5	28.7	29.1	24.1	28.1	31.7	33.5	34.4	33.9	30.5									
11-year	19.2	18.9	23.7	24.9	27.7	27.9	23.2	28.0	31.4	32.3	33.7	33.3										
12-year	18.7	18.4	23.0	24.2	27.5	27.2	22.8	27.2	30.4	31.4	33.2											
13-year	18.2	17.7	22.3	23.8	26.7	26.7	22.4	26.1	29.3	30.1												
14-year	17.7	17.4	21.7	23.1	26.5	26.1	22.2	25.5	28.9													
15-year	17.1	16.8	21.0	22.7	25.9	25.5	22.1	23.9														
16-year	16.7	16.3	20.7	22.3	25.7	24.9	20.7															
17-year	16.1	16.1	20.0	21.8	25.4	24.9																
18-year	15.9	15.8	19.5	21.3	25.4																	
19-year	15.6	15.1	19.0	20.9																		
20-year	15.2	14.7	18.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 4.14  
Cancer of the Female Breast (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	94.4	95.1	96.3	97.1	97.1	97.0	97.4	97.5	97.5	97.5	97.3	97.5	97.8	97.7	97.8	97.7	97.7	97.7	97.8	97.6	97.8	98.0
2-year	88.7	89.9	92.3	93.8	94.0	93.7	94.4	94.9	95.1	95.3	95.1	95.4	95.4	95.6	95.7	95.6	96.0	95.7	96.0	95.7	95.9	
3-year	83.1	84.6	88.3	90.5	91.3	90.9	92.0	92.9	93.1	93.4	92.8	93.5	93.3	93.2	93.8	93.8	94.0	93.7	93.9	93.8		
4-year	78.4	80.2	85.0	87.8	88.8	88.9	89.9	91.0	91.2	91.6	91.0	91.7	91.5	91.3	91.9	92.2	92.4	92.3	92.4			
5-year	74.6	76.3	82.2	85.6	86.8	86.7	88.4	89.5	89.5	90.2	89.4	90.2	89.7	89.9	90.5	90.7	91.1	90.6				
6-year	71.4	73.4	79.9	83.8	85.4	85.0	86.9	88.3	88.0	89.0	88.2	88.7	88.6	88.5	89.1	89.6	89.7					
7-year	68.6	70.6	77.8	82.1	83.8	83.8	85.9	87.1	86.9	87.7	86.8	87.6	87.4	87.4	87.9	88.5						
8-year	66.4	68.3	76.3	80.9	82.6	82.4	84.9	85.8	85.8	86.3	85.9	86.4	86.3	86.4	87.2							
9-year	64.2	66.4	74.6	79.7	81.3	81.4	83.7	84.6	84.9	85.2	85.2	85.5	85.8	85.4								
10-year	62.4	64.5	73.3	78.7	80.5	80.3	82.6	83.4	84.0	84.4	84.4	84.4	84.9	84.6								
11-year	60.8	62.7	72.1	77.6	79.4	79.5	81.7	82.6	82.8	83.5	83.5	84.3										
12-year	59.3	61.5	70.8	76.7	78.4	78.6	81.0	82.0	82.3	82.5	82.3											
13-year	58.1	60.4	69.8	75.8	77.3	77.5	80.0	81.0	81.5	81.6												
14-year	57.1	59.1	69.0	74.9	76.7	76.8	79.2	80.3	80.4													
15-year	56.0	58.3	68.0	74.1	75.8	76.1	78.3	79.3														
16-year	55.1	57.2	67.2	73.2	74.8	75.5	77.2															
17-year	54.1	56.2	66.4	72.3	73.9	74.7																
18-year	53.3	55.5	65.7	71.6	72.6																	
19-year	52.5	54.9	65.0	70.9																		
20-year	51.8	54.1	64.4																			
21-year	51.1	53.4	63.7																			
22-year	50.5	52.7	63.1																			
23-year	49.9	52.0	62.5																			
24-year	49.3	51.4	61.8																			
25-year	48.5	50.9																				
26-year	48.2	50.5																				
27-year	47.8	49.9																				
28-year	47.3	49.3																				
29-year	46.8	48.4																				
30-year	46.4																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 4.15  
Cancer of the Female Breast (Ages <50, Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	96.6	97.4	97.9	98.0	97.9	97.7	98.0	98.3	98.6	98.4	98.2	98.5	98.7	98.5	98.8	98.8	99.0	98.7	98.8	98.6	99.0	98.8
2-year	90.7	91.2	92.5	93.8	93.6	93.8	94.7	95.1	95.0	95.6	94.6	95.7	96.0	95.9	96.1	96.7	97.1	96.4	96.4	96.3	97.0	
3-year	84.5	85.5	87.3	89.7	90.0	90.8	91.6	92.2	92.2	93.0	91.6	93.2	93.7	93.2	93.8	94.8	95.1	94.0	94.2	93.8		
4-year	79.9	80.9	83.3	86.3	86.6	88.1	88.7	89.5	90.0	90.6	89.3	90.6	91.8	91.1	92.1	93.0	93.4	92.4	92.5			
5-year	76.1	77.0	80.1	83.8	84.1	85.5	86.8	87.3	88.1	89.0	87.3	88.6	89.8	89.4	90.7	91.1	91.8	90.7				
6-year	73.2	74.1	77.9	81.7	82.2	83.3	84.7	85.4	86.1	87.4	85.3	86.8	88.1	87.8	89.3	89.5	90.3					
7-year	70.8	71.5	75.8	80.0	80.2	81.7	83.2	83.7	84.8	85.6	83.5	85.3	86.8	86.2	88.2	88.6						
8-year	68.9	69.5	74.1	78.5	78.7	80.1	81.5	82.3	83.5	83.8	82.1	84.2	85.6	85.1	87.3							
9-year	67.0	67.7	72.6	77.3	77.6	79.0	80.5	80.8	82.5	82.5	81.0	83.1	84.9	84.1								
10-year	65.5	66.3	71.4	76.3	76.3	77.6	79.2	79.8	81.5	81.6	80.1	82.3	83.9									
11-year	64.2	65.0	70.3	75.3	75.5	76.7	78.2	78.9	80.3	80.8	79.2	81.5										
12-year	62.8	64.0	69.3	74.4	74.6	76.0	77.3	78.1	79.8	80.0	78.3											
13-year	61.6	63.0	68.3	73.4	73.7	74.7	76.4	77.5	79.1	79.2												
14-year	60.9	61.9	67.6	72.8	73.0	74.0	75.4	77.1	77.9													
15-year	60.1	61.1	66.8	72.1	72.2	73.3	74.7	76.5														
16-year	59.4	60.4	66.1	71.3	71.4	72.9	74.0															
17-year	58.9	59.7	65.6	70.7	70.3	72.2																
18-year	58.3	59.1	64.9	70.1	69.2																	
19-year	57.6	58.7	64.4	69.5																		
20-year	57.0	58.1	63.9																			
21-year	56.3	57.3	63.3																			
22-year	55.7	56.6	62.8																			
23-year	55.1	56.0	62.3																			
24-year	54.5	55.4	61.9																			
25-year	53.9	55.0																				
26-year	53.6	54.4																				
27-year	53.0	53.9																				
28-year	52.6	53.3																				
29-year	52.2	52.8																				
30-year	51.9																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 4.16  
Cancer of the Female Breast (Ages 50+, Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	93.7	94.4	95.8	96.8	96.8	96.7	97.1	97.2	97.2	97.2	97.0	97.2	97.5	97.5	97.4	97.4	97.3	97.4	97.5	97.3	97.4	97.8
2-year	88.0	89.6	92.3	93.8	94.1	93.6	94.3	94.9	95.2	95.3	95.2	95.4	95.2	95.5	95.6	95.3	95.7	95.5	95.8	95.6	95.6	
3-year	82.6	84.3	88.6	90.7	91.8	91.0	92.1	93.1	93.4	93.6	93.2	93.6	93.1	93.2	93.8	93.4	93.6	93.6	93.8	93.9		
4-year	77.9	79.9	85.6	88.4	89.6	89.1	90.3	91.6	91.7	92.0	91.6	92.1	91.4	91.4	91.8	92.0	92.1	92.3	92.4			
5-year	74.1	76.1	83.0	86.3	87.8	87.1	88.9	90.3	90.0	90.6	90.2	90.7	89.7	90.1	90.4	90.6	90.8	90.5				
6-year	70.8	73.1	80.5	84.6	86.6	85.6	87.7	89.4	88.7	89.5	89.3	89.4	88.8	88.8	89.1	89.6	89.6					
7-year	67.9	70.4	78.6	82.9	85.1	84.6	86.8	88.4	87.7	88.4	88.0	88.4	87.7	87.8	87.8	88.6						
8-year	65.6	68.0	77.1	81.9	84.1	83.3	86.2	87.1	86.6	87.3	87.2	87.2	86.6	87.0	87.2							
9-year	63.3	65.9	75.3	80.7	82.7	82.3	84.9	86.1	85.8	86.2	86.8	86.3	86.2	86.0								
10-year	61.3	63.8	73.9	79.6	82.1	81.4	83.8	84.8	85.0	85.5	85.9	85.9	84.9									
11-year	59.5	61.8	72.7	78.5	81.0	80.6	83.0	84.0	83.8	84.5	85.1	85.3										
12-year	58.0	60.6	71.3	77.6	79.9	79.6	82.4	83.5	83.2	83.4	83.8											
13-year	56.7	59.4	70.3	76.6	78.7	78.7	81.3	82.3	82.4	82.6												
14-year	55.6	58.1	69.4	75.7	78.2	77.9	80.8	81.5	81.4													
15-year	54.4	57.2	68.4	74.8	77.2	77.3	79.6	80.2														
16-year	53.3	55.9	67.5	73.8	76.1	76.5	78.4															
17-year	52.1	54.8	66.6	72.8	75.3	75.7																
18-year	51.2	54.0	65.7	72.0	73.9																	
19-year	50.3	53.3	65.1	71.2																		
20-year	49.5	52.4	64.3																			
21-year	48.8	51.6	63.5																			
22-year	48.2	51.0	62.9																			
23-year	47.6	50.2	62.1																			
24-year	46.9	49.5	61.3																			
25-year	45.9	49.0																				
26-year	45.6	48.7																				
27-year	45.2	48.0																				
28-year	44.8	47.3																				
29-year	44.1	46.1																				
30-year	43.6																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 5.9  
Cancer of the Cervix Uteri (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	86.6	87.2	87.1	87.7	89.2	89.0	89.3	88.1	89.6	88.4	85.7	87.9	86.6	86.4	87.2	86.2	88.3	87.3	88.8	87.6	84.8	86.8
2-year	77.8	77.2	77.9	79.5	82.2	81.8	80.1	81.3	82.9	81.1	79.1	79.6	79.0	77.3	77.3	78.5	78.6	79.3	79.6	79.5	75.5	
3-year	73.2	72.7	73.2	75.1	78.8	77.9	75.7	76.7	78.4	76.5	75.5	74.9	75.7	73.3	72.3	75.6	74.5	75.5	74.0	73.0		
4-year	70.3	69.6	70.4	72.2	76.0	74.7	73.2	74.0	76.1	74.2	72.4	72.5	72.3	69.9	69.9	73.4	72.7	72.4	70.7			
5-year	68.3	67.6	68.6	70.3	74.9	73.5	71.7	72.5	74.4	72.2	70.4	69.8	70.1	67.5	68.1	71.7	70.8	69.4				
6-year	67.1	65.7	67.3	68.9	73.7	72.8	70.1	70.9	73.4	71.1	69.1	69.0	68.5	66.0	67.2	69.7	69.8					
7-year	66.0	64.1	66.1	68.0	72.5	71.6	69.6	69.7	72.9	70.3	67.8	68.1	67.1	65.2	66.8	68.5						
8-year	65.0	62.8	65.0	67.1	71.8	70.7	69.2	69.4	72.5	70.0	67.3	67.7	65.8	63.5	65.6							
9-year	64.3	62.1	64.3	66.2	70.8	69.2	67.6	68.7	72.1	68.9	66.8	67.3	65.3	62.6								
10-year	63.1	61.4	63.7	65.5	70.0	68.7	67.0	67.7	70.7	68.3	66.6	66.8	64.9									
11-year	62.4	60.8	63.0	64.9	69.6	68.1	66.1	67.1	69.2	67.8	65.7	66.3										
12-year	61.7	60.0	62.2	64.3	68.5	66.8	65.8	66.1	68.6	66.7	64.6											
13-year	61.1	59.4	61.6	63.7	67.1	66.3	65.5	64.7	67.6	65.7												
14-year	60.4	58.6	61.0	63.2	66.5	65.5	65.2	64.5	66.9													
15-year	59.7	57.8	60.3	62.5	66.2	64.8	64.8	64.2														
16-year	59.2	57.1	59.6	61.9	65.4	64.3	63.0															
17-year	58.6	56.1	58.8	61.4	64.6	63.3																
18-year	58.1	55.3	58.6	60.6	64.0																	
19-year	57.2	54.8	58.2	60.1																		
20-year	56.5	54.0	57.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 6.15  
Cancer of the Colon and Rectum (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	74.0	77.1	80.0	80.9	79.4	81.3	80.3	82.0	82.3	81.9	83.1	83.3	82.4	83.5	84.0	83.6	84.0	84.7	84.3	84.2	83.7	84.0
2-year	63.0	66.8	71.1	72.4	71.3	73.3	72.4	74.5	74.5	74.4	75.6	76.8	75.8	76.6	77.0	77.1	77.1	78.3	77.3	77.2	76.6	
3-year	56.8	60.5	65.7	67.2	65.8	68.6	67.2	69.4	70.0	70.2	71.1	72.2	70.8	71.6	72.5	72.1	72.3	73.2	72.3	71.9		
4-year	53.0	56.4	61.8	63.2	61.9	65.0	64.2	66.3	66.9	66.9	68.2	69.0	67.7	68.3	68.8	68.4	69.0	69.9	68.6			
5-year	50.4	53.7	59.3	60.7	59.7	62.6	61.5	63.3	64.5	64.8	66.1	66.3	65.3	65.7	66.2	66.1	66.6	67.2				
6-year	48.6	51.8	57.5	59.0	57.3	61.3	59.8	61.4	63.0	63.1	64.1	64.4	63.5	63.9	64.5	64.5	64.5					
7-year	47.4	50.3	56.0	57.4	55.5	60.2	58.8	60.1	61.9	61.6	62.2	63.0	62.1	62.8	62.8	62.8						
8-year	46.4	49.3	55.0	56.2	54.9	59.4	57.9	59.3	60.6	60.2	61.2	62.0	61.3	61.7	61.7							
9-year	45.8	48.4	54.1	55.4	54.6	58.7	57.2	58.0	59.7	59.5	60.3	60.7	60.1	60.9								
10-year	45.1	47.8	53.3	54.6	53.9	58.1	56.4	57.3	59.2	58.9	59.6	60.4	58.9									
11-year	44.5	47.2	52.8	54.1	53.0	57.5	55.6	56.4	58.4	58.0	59.1	59.6										
12-year	44.1	46.7	52.4	53.5	52.3	57.4	55.2	56.2	57.8	57.4	58.1											
13-year	43.6	46.4	51.7	53.0	51.6	56.8	54.9	55.6	57.6	57.0												
14-year	43.1	45.9	51.4	52.6	51.1	55.9	54.1	55.4	56.8													
15-year	42.8	45.6	50.8	52.2	50.5	55.3	53.4	55.3														
16-year	42.3	45.1	50.6	52.2	49.9	54.8	52.6															
17-year	41.9	44.7	50.0	51.5	49.4	53.8																
18-year	41.5	44.3	49.7	51.0	48.8																	
19-year	41.5	43.8	49.4	50.4																		
20-year	41.3	43.6	48.9																			
21-year	40.9	42.9	48.9																			
22-year	40.6	42.4	48.7																			
23-year	40.1	42.2	48.2																			
24-year	39.7	41.8	47.5																			
25-year	39.4	41.3																				
26-year	38.9	40.8																				
27-year	38.4	40.4																				
28-year	38.3	39.9																				
29-year	37.8	39.8																				
30-year	37.3																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 6.16  
Cancer of the Colon and Rectum (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	74.0	78.0	81.0	81.7	81.0	82.6	81.3	82.1	83.4	83.6	85.1	83.2	83.2	84.5	84.6	84.7	85.4	86.3	85.5	85.4	84.0	84.6
2-year	63.0	67.2	72.4	73.2	72.6	75.0	73.6	74.4	75.2	76.3	77.4	76.6	76.3	77.9	77.9	78.2	78.4	79.3	78.4	78.3	76.9	
3-year	56.3	60.6	66.7	67.9	66.9	69.7	68.2	68.8	70.5	72.0	72.8	72.0	71.1	72.5	73.1	72.9	73.4	74.0	73.2	72.8		
4-year	52.1	56.2	62.4	63.5	63.1	65.3	65.2	65.4	67.5	68.9	69.9	68.7	67.8	69.1	68.8	68.7	69.5	70.2	69.1			
5-year	49.4	53.3	59.7	60.5	60.0	62.4	62.3	62.4	64.9	66.0	67.3	65.7	65.4	66.1	65.8	66.5	66.7	67.5				
6-year	47.2	51.2	57.8	58.5	57.3	61.0	60.3	60.1	63.7	63.7	65.0	63.4	62.8	64.2	63.7	64.6	64.3					
7-year	45.9	49.5	56.2	56.8	55.7	59.8	59.6	58.7	62.5	61.9	63.1	61.7	61.5	62.6	61.5	63.0						
8-year	44.8	48.4	55.3	55.3	55.1	59.4	58.3	57.4	61.1	60.0	62.4	60.4	60.2	61.5	60.5							
9-year	44.1	47.5	54.3	54.5	54.6	58.9	57.4	56.2	60.0	59.7	61.4	59.4	58.9	60.8								
10-year	43.3	46.7	53.5	53.6	53.9	58.0	56.7	55.5	59.1	58.6	60.4	59.2	57.5									
11-year	42.8	46.0	53.1	53.1	53.1	57.3	55.8	54.5	58.4	57.7	59.6	58.4										
12-year	42.1	45.6	52.5	52.7	52.2	57.0	55.6	54.0	57.8	57.0	59.0											
13-year	41.7	45.4	51.9	51.9	51.7	56.6	55.2	53.5	57.2	56.8												
14-year	41.0	44.7	51.7	51.4	50.7	55.7	54.5	53.2	56.2													
15-year	40.7	44.5	51.1	50.9	49.8	55.4	54.3	53.0														
16-year	40.3	44.3	51.0	50.8	49.2	55.1	53.1															
17-year	39.7	43.7	50.5	50.4	48.8	54.2																
18-year	39.4	43.3	50.2	49.8	47.9																	
19-year	39.3	42.8	49.8	49.5																		
20-year	39.2	42.5	49.4																			
21-year	38.9	41.7	49.3																			
22-year	38.4	41.1	49.3																			
23-year	38.0	40.8	48.6																			
24-year	37.6	40.3	47.9																			
25-year	37.2	39.9																				
26-year	36.3	39.2																				
27-year	35.8	38.7																				
28-year	35.6	38.3																				
29-year	35.2	38.1																				
30-year	34.2																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 6.17  
Cancer of the Colon and Rectum (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	73.9	76.3	78.9	80.0	77.9	79.9	79.3	82.0	81.2	80.3	81.0	83.4	81.7	82.5	83.4	82.5	82.5	83.0	83.0	82.8	83.3	83.3
2-year	63.0	66.4	69.8	71.6	70.0	71.6	71.1	74.6	73.9	72.5	73.7	77.1	75.2	75.3	76.0	76.0	75.9	77.2	76.0	75.9	76.2	
3-year	57.4	60.3	64.6	66.4	64.6	67.4	66.2	70.0	69.5	68.5	69.3	72.3	70.5	70.6	71.8	71.3	71.2	72.5	71.3	71.0		
4-year	53.8	56.6	61.2	63.0	60.8	64.7	63.1	67.2	66.2	64.9	66.5	69.3	67.6	67.5	68.8	68.0	68.4	69.6	68.2			
5-year	51.4	54.1	58.9	60.9	59.4	62.7	60.6	64.1	64.2	63.5	64.8	66.8	65.3	65.3	66.6	65.8	66.5	67.0				
6-year	49.8	52.3	57.2	59.5	57.3	61.5	59.2	62.7	62.4	62.4	63.2	65.5	64.2	63.5	65.3	64.4	64.8					
7-year	48.7	51.0	55.7	58.1	55.4	60.6	57.9	61.3	61.3	61.3	61.3	64.3	62.7	63.0	64.2	62.6						
8-year	47.9	50.1	54.6	57.1	54.7	59.4	57.6	61.0	60.2	60.4	60.1	63.6	62.4	62.0	63.0							
9-year	47.3	49.3	53.9	56.3	54.4	58.5	57.0	59.8	59.5	59.3	59.2	62.1	61.3	61.0								
10-year	46.7	48.7	53.1	55.5	53.8	58.0	56.1	59.0	59.3	59.2	58.7	61.5	60.3									
11-year	46.1	48.2	52.5	55.0	53.0	57.6	55.4	58.3	58.4	58.2	58.5	60.8										
12-year	45.9	47.7	52.3	54.4	52.4	57.6	54.7	58.3	57.9	57.7	57.2											
13-year	45.5	47.4	51.4	54.1	51.6	56.9	54.5	57.8	57.9	57.0												
14-year	45.1	47.0	51.0	53.8	51.4	56.0	53.6	57.5	57.4													
15-year	44.6	46.6	50.5	53.4	51.2	55.1	52.3	57.5														
16-year	44.2	45.9	50.1	53.4	50.6	54.5	51.9															
17-year	44.0	45.6	49.5	52.6	50.0	53.3																
18-year	43.4	45.2	49.2	52.2	49.4																	
19-year	43.4	44.7	48.9	51.2																		
20-year	43.1	44.6	48.4																			
21-year	42.7	44.0	48.4																			
22-year	42.5	43.5	48.0																			
23-year	41.9	43.3	47.7																			
24-year	41.6	43.2	47.1																			
25-year	41.4	42.4																				
26-year	41.2	42.2																				
27-year	40.6	41.9																				
28-year	40.6	41.3																				
29-year	40.0	41.2																				
30-year	39.9																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 7.9  
Cancer of the Corpus And Uterus, NOS (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	93.7	91.4	92.2	92.1	92.9	91.5	93.1	93.4	93.8	93.6	92.1	92.0	92.8	92.8	92.7	92.8	93.2	93.4	92.8	93.4	92.1	93.0
2-year	90.1	86.3	87.5	88.1	88.4	88.0	88.9	89.7	89.5	89.5	88.1	88.1	88.5	88.2	89.0	89.4	89.5	88.7	88.2	88.9	87.7	
3-year	87.8	83.4	84.8	85.6	85.9	85.7	86.1	86.5	87.2	87.4	85.7	85.6	86.0	85.4	85.7	87.1	87.3	86.0	85.6	86.8		
4-year	86.3	82.0	83.4	84.0	84.6	84.6	85.1	84.4	85.5	85.9	84.1	83.7	84.6	83.7	84.1	85.5	85.7	84.3	84.4			
5-year	85.8	80.9	82.3	83.3	84.1	83.3	84.0	83.2	84.2	85.2	83.2	82.8	83.4	82.6	82.9	84.8	83.9	82.7				
6-year	85.1	80.3	81.7	82.2	83.4	82.1	83.3	82.5	83.7	84.4	82.2	82.4	82.5	81.6	81.8	84.2	83.2					
7-year	84.7	79.8	81.2	81.9	82.9	81.2	82.5	82.2	82.6	83.9	81.4	81.3	81.9	80.6	81.1	83.6						
8-year	84.5	79.1	80.8	81.2	82.4	80.4	81.5	81.9	81.9	83.2	80.7	80.9	81.8	80.1	80.6							
9-year	84.5	78.7	80.4	81.0	81.4	79.8	81.0	81.3	81.9	83.2	80.0	80.3	81.2	79.7								
10-year	84.3	78.5	80.2	80.5	81.1	79.5	81.0	81.0	81.2	82.8	79.8	80.0	80.1									
11-year	84.0	78.0	79.9	80.4	81.0	79.5	81.0	81.0	81.2	81.8	78.9	80.0										
12-year	83.9	77.8	79.5	79.9	80.8	79.5	81.0	80.7	80.8	81.7	78.3											
13-year	83.9	77.5	79.2	79.6	80.6	79.1	81.0	80.5	80.2	81.3												
14-year	83.7	77.1	78.9	79.2	80.1	78.8	81.0	79.5	79.8													
15-year	83.6	76.8	78.5	79.1	79.6	78.4	80.8	79.3														
16-year	83.4	76.1	78.0	78.6	79.2	77.2	80.6															
17-year	83.4	75.9	77.9	78.2	78.7	76.1																
18-year	83.4	75.5	77.8	77.7	77.7																	
19-year	83.4	74.8	77.6	77.0																		
20-year	83.4	74.7	76.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 8.9  
Cancer of the Esophagus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	25.9	29.9	34.9	38.5	40.3	42.0	40.1	40.8	44.2	46.1	46.2	41.9	46.6	48.2	45.6	47.6	49.9	47.8	48.9	49.6	49.2	51.1
2-year	11.4	14.3	19.0	21.8	22.6	24.3	23.9	23.9	26.8	28.4	29.2	25.9	30.4	30.2	31.2	30.6	32.9	32.3	30.7	33.8	32.1	
3-year	7.7	10.0	13.5	16.3	16.8	18.6	17.5	18.3	20.8	23.9	22.9	20.9	23.8	25.8	24.2	25.2	27.0	24.5	24.4	27.7		
4-year	5.9	8.2	10.8	13.7	13.2	15.9	14.3	14.2	18.3	20.6	19.1	17.9	20.0	22.2	21.4	21.9	23.4	21.8	21.3			
5-year	4.9	7.0	9.5	12.2	11.6	15.0	12.4	12.6	17.4	18.9	17.8	16.8	17.1	20.2	18.9	20.1	21.6	18.7				
6-year	4.3	6.1	8.5	11.0	10.8	13.8	11.3	11.6	15.9	17.9	15.8	15.3	14.3	19.6	17.4	18.7	19.4					
7-year	3.8	5.6	7.7	10.2	10.2	12.9	10.7	11.3	14.7	16.7	14.7	14.9	13.1	18.2	15.6	17.8						
8-year	3.4	4.9	7.0	9.5	9.6	12.2	9.8	9.8	14.1	15.8	13.7	13.6	12.8	17.9	14.6							
9-year	3.2	4.5	6.4	9.0	8.9	11.5	9.3	9.6	13.4	15.6	13.4	13.1	12.7	16.5								
10-year	2.9	4.3	6.0	8.3	8.6	10.7	9.2	9.4	12.9	15.1	13.2	13.0	11.6									
11-year	2.7	3.9	5.4	7.8	7.6	9.7	9.0	9.1	12.7	14.3	12.2	13.0										
12-year	2.6	3.8	4.9	7.1	7.2	9.3	7.5	8.5	11.8	14.0	11.8											
13-year	2.4	3.5	4.6	7.0	6.8	9.3	7.0	8.5	10.9	12.2												
14-year	2.4	3.4	4.3	6.6	5.7	8.9	6.3	8.4	10.3													
15-year	2.4	3.4	4.2	6.1	5.5	8.7	6.0	7.6														
16-year	2.3	3.2	3.7	5.8	4.9	7.8	5.9															
17-year	2.3	3.0	3.2	5.5	4.9	6.9																
18-year	2.2	2.7	3.1	5.3	4.9																	
19-year	2.2	2.5	2.9	4.9																		
20-year	2.1	2.4	2.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 8.10  
Cancer of the Esophagus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	23.9	29.2	34.1	38.9	39.9	43.2	40.6	41.0	43.5	47.5	47.1	43.1	46.2	47.6	46.7	48.5	51.6	48.7	50.2	48.5	48.7	51.7
2-year	10.0	13.8	18.4	21.6	22.8	24.8	24.7	24.3	26.3	28.7	29.6	26.4	29.8	30.2	31.1	30.9	33.2	32.8	30.8	33.0	31.8	
3-year	6.8	9.2	13.1	16.4	16.7	18.2	18.3	18.5	20.6	23.6	23.0	21.3	23.1	25.8	24.1	25.9	27.4	24.9	24.9	26.7		
4-year	5.1	7.3	10.3	13.4	13.0	15.1	15.2	14.2	18.0	19.6	19.2	18.1	19.5	22.4	20.8	22.8	23.6	21.9	21.2			
5-year	4.2	6.0	9.3	12.0	11.8	13.9	13.0	12.1	17.2	17.3	18.3	16.8	16.7	20.0	18.4	21.0	21.9	18.8				
6-year	3.7	5.1	8.4	10.8	11.0	12.9	11.8	11.5	16.0	16.4	16.2	15.4	13.8	19.3	17.1	19.4	19.4					
7-year	3.3	4.5	7.6	10.2	10.7	11.9	11.5	11.2	14.9	15.4	15.3	15.3	12.6	18.3	15.3	18.4						
8-year	3.0	4.0	6.9	9.3	9.9	11.2	10.3	9.4	14.7	14.6	14.5	13.7	12.1	17.8	14.0							
9-year	2.8	3.6	6.5	8.8	9.6	10.6	10.0	9.3	14.0	14.3	14.1	13.3	12.1	17.2								
10-year	2.7	3.4	6.2	7.9	9.2	9.9	9.7	9.3	13.2	14.0	13.7	13.3	11.5									
11-year	2.5	3.3	5.7	7.5	8.4	8.9	9.5	9.0	13.1	13.1	12.9	13.3										
12-year	2.4	3.2	5.1	6.8	7.7	8.6	8.4	8.8	12.7	12.8	12.5											
13-year	2.3	3.0	4.6	6.8	7.1	8.6	7.7	8.8	11.7	10.7												
14-year	2.2	3.0	4.2	6.6	6.3	8.3	6.9	8.8	10.9													
15-year	2.2	3.0	4.0	6.1	5.9	8.3	6.3	7.8														
16-year	2.2	2.8	3.4	5.9	5.3	8.1	6.1															
17-year	2.2	2.8	2.9	5.5	5.3	7.0																
18-year	2.2	2.5	2.8	5.3	5.3																	
19-year	2.1	2.3	2.5	5.1																		
20-year	2.0	2.2	2.3																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 8.11  
Cancer of the Esophagus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	31.2	31.6	37.1	37.3	41.4	38.4	38.8	39.9	46.6	41.6	42.9	38.2	48.0	50.0	41.7	44.9	44.3	44.3	44.4	54.0	50.9	48.9
2-year	15.1	15.6	20.7	22.4	22.2	22.9	21.6	22.5	28.6	27.4	27.9	24.3	32.4	29.9	31.5	29.5	31.9	30.2	30.5	37.3	33.2	
3-year	10.0	12.0	14.5	16.2	17.0	19.8	15.1	17.6	21.3	24.6	22.7	19.6	26.2	25.8	24.5	22.6	25.4	23.0	22.7	31.8		
4-year	7.9	10.5	12.3	14.5	13.7	18.2	11.7	14.3	18.9	23.8	18.6	17.3	21.8	21.8	23.5	18.7	22.3	21.3	21.4			
5-year	6.5	9.3	10.0	12.9	10.7	18.2	10.6	14.1	17.9	23.8	16.1	16.9	18.6	20.7	20.6	17.0	20.8	18.4				
6-year	5.9	8.6	8.5	11.8	9.9	16.3	9.8	11.9	15.2	22.7	14.2	14.8	16.3	20.4	18.4	16.3	19.6					
7-year	5.2	8.3	8.0	10.2	9.0	15.7	8.1	11.7	13.4	20.7	12.3	13.4	14.9	18.0	16.9	15.5						
8-year	4.4	7.1	7.3	10.0	8.7	14.7	8.1	10.8	12.0	19.6	10.7	13.1	14.9	17.7	16.5							
9-year	4.0	6.5	6.3	9.5	7.1	14.1	7.4	10.5	10.9	19.3	10.7	12.3	14.2	14.2								
10-year	3.5	6.5	5.3	9.2	6.6	12.8	7.4	9.5	10.9	18.3	10.7	12.0	11.7									
11-year	3.3	5.4	4.8	8.8	5.6	11.8	7.4	9.3	10.1	17.6	9.5	12.0										
12-year	3.1	5.2	4.6	7.9	5.6	11.4	5.2	7.6	8.2	17.3	8.8											
13-year	2.8	4.7	4.6	7.0	5.6	11.4	4.6	7.6	7.5	16.4												
14-year	2.8	4.5	4.5	6.4	4.2	10.8	4.6	6.8	7.5													
15-year	2.8	4.5	4.5	6.1	4.2	9.0	4.6	6.8														
16-year	2.7	3.8	4.2	5.5	3.7	7.1	4.6															
17-year	2.4	3.2	3.9	5.4	3.7	6.5																
18-year	2.2	3.0	3.8	5.2	3.7																	
19-year	2.2	2.8	3.7	4.5																		
20-year	2.2	2.8	3.3																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.9  
Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	86.9	89.4	90.7	92.0	92.8	91.5	93.6	94.6	91.0	92.4	94.0	92.8	93.2	91.5	93.4	92.5	93.3	94.7	92.2	91.7	93.6	94.5
2-year	80.8	83.6	86.3	87.7	88.6	88.1	90.9	90.5	87.7	90.6	90.8	89.8	92.2	89.6	90.9	90.2	92.5	92.7	89.6	90.4	92.2	
3-year	76.5	80.0	82.9	85.1	86.5	86.7	89.3	88.3	85.4	88.7	88.5	88.4	89.9	87.4	90.3	89.0	90.7	91.6	88.1	89.4		
4-year	73.7	77.4	80.5	83.2	83.4	84.6	88.4	86.6	84.2	87.9	86.6	86.1	88.1	86.1	89.4	88.6	89.0	90.6	87.0			
5-year	71.4	74.8	79.0	81.6	82.2	83.2	87.2	84.9	83.4	86.4	85.2	85.1	87.5	86.0	88.3	88.3	88.4	90.4				
6-year	69.0	72.3	77.4	80.0	80.1	81.7	85.9	83.7	82.2	85.6	84.3	84.7	87.0	84.9	87.9	87.0	86.8					
7-year	67.1	70.6	75.1	78.6	78.9	80.0	85.2	83.0	80.9	84.8	84.3	83.3	86.3	84.3	87.2	86.3						
8-year	65.0	69.2	74.0	77.7	78.4	79.3	84.7	82.4	80.0	83.8	83.8	82.4	85.6	83.4	85.6							
9-year	63.0	67.8	73.2	76.8	77.2	78.2	84.4	81.4	79.0	82.9	82.8	81.3	84.7	82.9								
10-year	61.7	66.7	72.6	76.0	76.6	76.7	83.8	80.2	78.1	82.9	81.8	80.5	84.3									
11-year	60.4	65.7	71.6	75.4	75.6	75.7	83.3	79.5	78.0	82.8	81.3	78.9										
12-year	59.4	64.6	70.8	74.6	75.5	74.8	82.8	79.2	77.5	82.3	81.1											
13-year	58.7	63.7	69.6	73.9	75.4	74.2	81.7	78.9	76.3	81.9												
14-year	57.4	62.6	68.5	73.5	75.4	73.5	80.0	78.3	76.2													
15-year	56.4	61.7	67.4	72.9	75.3	73.1	79.2	77.0														
16-year	55.6	60.7	66.7	72.4	75.0	73.1	78.8															
17-year	54.7	59.3	66.1	71.8	74.6	72.3																
18-year	53.7	58.5	65.5	71.1	73.7																	
19-year	53.1	57.8	64.8	70.2																		
20-year	52.1	56.8	64.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.10  
Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	85.9	89.4	89.8	91.2	92.2	92.7	92.1	94.3	89.3	90.8	92.9	90.8	93.0	89.7	93.3	91.7	92.4	93.4	93.0	90.2	92.6	93.6
2-year	80.2	83.6	84.7	85.8	88.0	88.6	89.5	91.0	86.1	88.4	89.1	88.2	92.2	88.4	90.7	89.2	91.6	91.4	89.4	89.4	91.5	
3-year	75.3	80.3	81.3	83.0	85.1	87.1	87.4	88.8	83.6	85.4	86.6	86.7	89.9	86.4	90.0	88.7	89.4	90.5	87.7	87.6		
4-year	71.7	77.2	78.3	80.8	81.0	85.1	86.9	86.5	82.8	83.7	85.1	84.8	86.8	85.9	88.7	87.6	87.6	89.1	86.9			
5-year	69.2	74.1	76.4	79.0	80.2	83.0	85.8	84.5	82.5	81.8	83.7	83.7	86.1	85.9	87.6	87.4	86.9	89.1				
6-year	66.5	71.4	74.6	77.1	78.8	81.9	83.5	83.5	80.5	80.9	82.1	83.0	86.1	83.9	86.8	85.7	84.9					
7-year	64.4	69.7	71.8	76.0	77.6	79.7	82.9	82.3	78.7	80.2	81.8	81.1	85.1	83.7	85.7	85.4						
8-year	62.4	68.2	70.4	74.8	76.5	78.6	82.2	81.8	77.5	79.1	81.4	79.9	84.2	82.7	83.0							
9-year	60.0	67.0	69.2	73.8	75.3	77.6	82.2	80.3	76.1	78.8	79.6	79.1	82.7	82.7								
10-year	58.9	65.7	68.6	73.2	75.3	75.3	81.0	78.3	75.1	78.7	78.2	78.4	82.1									
11-year	57.5	64.7	67.1	72.6	74.3	74.1	80.4	77.6	75.1	77.9	77.3	75.8										
12-year	56.4	63.3	66.0	71.9	74.2	72.6	80.3	77.2	74.1	77.2	77.0											
13-year	55.7	62.6	64.4	71.0	74.2	72.0	78.5	77.0	71.6	76.6												
14-year	54.4	61.2	63.2	70.6	74.2	70.6	76.8	76.0	71.4													
15-year	53.1	60.5	62.0	69.9	74.2	70.0	75.8	73.1														
16-year	52.4	59.5	61.1	69.5	74.2	70.0	75.4															
17-year	51.1	58.1	60.7	68.8	74.2	69.6																
18-year	50.2	57.0	60.0	68.0	73.0																	
19-year	49.5	56.6	59.4	67.3																		
20-year	48.6	55.2	58.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 9.11  
Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	88.2	89.5	91.8	93.0	93.7	90.0	95.1	94.9	92.9	94.5	95.3	95.2	93.4	93.3	93.4	93.4	94.5	96.1	91.3	93.4	94.7	95.6
2-year	81.6	83.7	88.3	89.9	89.3	87.4	92.3	89.8	89.4	93.6	92.7	91.6	92.2	90.9	91.1	91.3	93.4	94.1	89.6	91.8	93.1	
3-year	78.1	79.7	85.0	87.6	88.1	86.2	91.3	87.6	87.5	93.1	90.8	90.2	90.0	88.3	90.6	89.4	92.4	92.9	88.4	91.4		
4-year	76.2	77.6	83.2	86.0	86.5	83.9	89.8	86.5	85.7	93.1	88.5	87.5	89.6	86.2	90.4	89.4	90.7	92.4	87.0			
5-year	74.4	75.7	82.1	84.7	84.6	83.5	88.5	85.3	84.4	92.5	87.1	86.7	89.1	86.1	89.2	89.3	90.2	91.6				
6-year	72.3	73.4	81.0	83.4	81.8	81.4	88.5	84.0	83.9	92.0	86.8	86.5	88.1	85.7	89.1	88.4	89.2					
7-year	70.8	71.8	79.2	81.7	80.6	80.4	87.7	83.6	83.2	91.1	86.8	85.7	87.8	84.9	89.0	87.3						
8-year	68.5	70.6	78.4	81.2	80.6	80.1	87.2	83.1	82.6	90.4	86.8	84.9	87.2	83.9	88.9							
9-year	66.9	68.9	78.1	80.3	79.4	78.9	86.6	82.6	82.2	88.5	86.7	83.5	87.0	83.0								
10-year	65.4	68.1	77.6	79.3	78.2	78.4	86.5	82.2	81.3	88.5	86.5	82.7	86.9									
11-year	64.2	67.1	77.2	78.8	77.4	77.5	86.1	81.7	80.8	88.5	86.4	82.3										
12-year	63.5	66.3	76.8	77.9	76.9	77.4	85.1	81.2	80.8	88.5	86.4											
13-year	62.5	65.2	76.1	77.5	76.1	77.1	84.9	80.8	80.8	88.5												
14-year	61.5	64.3	75.1	77.0	76.1	76.8	83.3	80.8	80.8													
15-year	60.7	63.3	74.0	76.5	75.9	76.8	82.6	80.8														
16-year	59.9	62.3	73.5	75.9	75.7	76.8	82.1															
17-year	59.4	61.0	72.8	75.4	75.1	75.7																
18-year	58.5	60.3	72.4	74.8	74.3																	
19-year	57.8	59.5	71.5	73.6																		
20-year	56.8	58.8	71.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.7  
Kaposi SarcomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	95.0	65.4	59.0	59.0	61.8	69.0	72.9	73.8	76.7	74.1	80.3	77.8	75.1	82.6	81.9	81.3	82.7	79.6	82.2	83.3	84.9	79.8
2-year	89.6	44.4	32.8	29.3	46.7	60.4	65.1	65.5	65.1	66.3	73.1	70.7	72.3	73.5	78.5	78.6	80.2	75.5	79.3	77.2	81.0	
3-year	88.7	35.9	19.8	18.2	42.8	54.0	62.1	61.1	61.5	60.1	67.1	67.1	66.7	70.9	74.7	76.2	78.5	74.3	76.1	74.4		
4-year	83.8	31.8	13.8	13.9	38.5	51.5	58.9	59.0	56.7	57.0	65.1	66.0	64.7	69.3	73.9	75.5	76.5	74.3	74.4			
5-year	83.8	27.7	10.5	11.7	35.7	48.3	56.6	58.5	55.8	54.1	63.5	60.2	64.5	68.2	71.9	73.3	74.5	73.7				
6-year	76.9	24.2	8.9	10.8	35.1	45.5	54.5	55.7	53.4	52.6	63.2	58.4	64.2	66.9	70.2	72.2	73.1					
7-year	76.8	23.2	7.7	10.2	33.3	44.8	49.7	53.1	52.8	52.6	62.4	58.4	60.4	66.7	68.1	71.1						
8-year	76.8	20.3	6.8	9.8	32.1	44.4	46.9	50.4	52.3	52.0	61.0	56.5	58.2	66.6	66.9							
9-year	76.8	18.9	6.1	9.5	31.0	42.6	44.5	49.8	52.3	50.5	58.9	56.4	56.5	65.4								
10-year	76.8	16.9	5.9	9.3	29.8	42.6	43.4	49.8	51.4	48.5	56.2	56.4	56.0									
11-year	74.7	15.6	5.7	9.1	28.8	42.1	42.0	49.1	50.2	46.2	56.2	56.4										
12-year	74.7	15.3	5.6	9.1	27.9	41.8	40.9	49.1	50.2	45.5	54.6											
13-year	74.7	14.6	5.2	9.1	27.4	41.8	39.9	47.7	50.2	45.0												
14-year	74.7	14.6	5.0	8.8	26.8	40.5	39.8	45.3	48.9													
15-year	74.7	14.6	4.9	8.6	26.2	40.3	39.8	43.9														
16-year	74.7	14.6	4.8	8.4	25.6	39.9	39.8															
17-year	74.7	14.3	4.8	8.3	25.3	38.7																
18-year	74.7	13.0	4.8	8.0	25.2																	
19-year	74.7	13.0	4.6	7.8																		
20-year	74.7	13.0	4.5																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.8  
Kaposi SarcomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	95.2	63.6	58.7	58.6	60.9	68.7	72.7	73.0	76.7	73.8	79.6	76.6	75.6	81.3	82.9	80.7	82.6	80.8	81.6	83.2	83.7	81.1
2-year	89.1	41.7	32.1	28.7	45.4	59.7	64.2	64.0	64.6	65.6	73.4	69.8	72.5	72.0	79.2	77.7	80.3	76.8	79.5	77.2	80.4	
3-year	86.8	33.4	18.9	17.5	41.8	53.7	60.7	59.6	61.0	59.5	68.2	66.9	67.1	69.0	75.7	75.6	78.3	75.5	75.8	73.9		
4-year	83.7	29.3	13.0	13.2	37.5	51.1	57.0	57.0	55.7	56.7	65.7	66.4	65.0	67.1	74.8	75.0	75.8	75.5	74.1			
5-year	83.6	25.6	9.6	11.0	35.0	48.0	55.6	56.1	54.6	54.1	63.4	60.1	64.6	65.5	72.6	72.7	73.5	74.8				
6-year	74.2	21.8	8.0	10.1	34.3	45.3	53.3	54.0	51.7	53.0	63.4	58.3	64.2	63.8	70.7	71.5	71.7					
7-year	74.1	20.5	6.8	9.5	32.4	44.5	49.1	52.4	51.0	53.0	63.2	58.3	60.0	63.8	68.4	70.3						
8-year	74.1	18.2	6.0	9.1	31.2	44.1	46.4	50.7	50.9	52.4	61.9	57.4	58.2	63.8	67.1							
9-year	74.1	16.9	5.4	8.8	30.2	42.2	43.9	50.1	50.9	50.7	60.1	57.1	57.7	63.8								
10-year	74.1	15.1	5.2	8.6	29.1	42.1	42.5	50.1	50.3	49.2	57.0	57.1	57.2									
11-year	69.0	13.8	5.0	8.4	28.2	41.7	41.5	49.3	48.9	46.8	56.9	57.1										
12-year	68.9	13.6	4.9	8.4	27.3	41.3	40.3	49.3	48.9	45.9	54.8											
13-year	68.9	13.0	4.6	8.3	26.7	41.3	39.3	47.8	48.6	45.3												
14-year	68.9	13.0	4.4	8.0	26.2	40.3	39.2	45.2	46.7													
15-year	68.9	12.9	4.4	7.8	25.8	40.1	39.2	43.8														
16-year	68.9	12.7	4.3	7.7	25.2	39.7	39.2															
17-year	68.9	12.7	4.3	7.5	25.0	38.5																
18-year	68.9	12.3	4.2	7.3	25.0																	
19-year	68.9	12.3	4.1	7.0																		
20-year	68.9	12.3	4.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 10.9  
Kaposi SarcomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	92.6	90.0	80.4	80.3	87.2	78.4	74.9	85.4	75.8	78.0	86.3	88.7	64.5	100.0	64.3	89.8	83.7	45.7	87.7	81.6	98.3	64.5
2-year	90.4	84.0	79.0	63.2	85.9	78.4	74.9	85.4	69.6	76.5	67.5	78.2	64.5	97.2	64.3	89.8	78.0	45.7	75.9	75.9	86.2	
3-year	90.4	73.4	74.3	57.2	74.5	64.5	74.9	85.0	65.8	67.3	52.1	66.4	55.9	97.2	57.0	81.1	78.0	45.7	75.9	75.9		
4-year	83.5	69.5	73.6	53.8	71.4	64.5	74.9	85.0	65.8	61.5	52.1	54.7	55.9	97.2	57.0	81.1	78.0	45.7	75.3			
5-year	81.4	61.0	73.6	52.5	53.7	55.2	69.1	85.0	65.8	52.5	52.1	54.7	55.9	97.2	57.0	81.1	78.0	45.7				
6-year	81.4	61.0	73.6	48.8	53.7	49.3	69.1	80.8	65.8	43.3	52.1	54.7	55.9	97.2	57.0	81.1	78.0					
7-year	81.4	61.0	73.6	48.6	53.7	49.3	58.1	54.5	65.8	43.3	50.9	54.7	55.9	97.2	57.0	81.1						
8-year	81.4	54.1	66.7	48.5	53.7	49.3	51.9	19.5	65.8	43.3	45.9	40.1	55.9	77.3	57.0							
9-year	81.4	51.0	66.1	47.6	50.7	49.3	51.9	19.5	65.8	43.3	38.5	40.1	21.2	77.3								
10-year	81.4	45.4	59.7	47.6	48.1	49.3	51.9	19.5	62.8	35.5	38.5	40.1	21.2									
11-year	81.4	42.7	59.7	47.6	40.3	49.3	46.8	19.5	62.8	35.5	38.5	40.1										
12-year	81.4	41.9	57.0	47.6	40.3	49.3	46.8	19.5	62.8	35.5	38.5											
13-year	81.4	41.0	52.4	47.6	40.3	38.4	46.8	19.5	62.8	35.5												
14-year	81.4	41.0	39.3	47.6	39.0	38.4	46.8	19.5	62.8													
15-year	81.4	41.0	33.4	47.6	27.5	38.4	46.8	0.0														
16-year	81.4	41.0	33.4	47.6	27.5	38.4	46.8															
17-year	81.4	29.3	33.4	47.6	15.6	38.4																
18-year	80.2	16.6	33.4	47.6	0.0																	
19-year	80.2	16.6	33.4	47.6																		
20-year	80.2	16.6	33.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 11.9  
Cancer of the Kidney and Renal Pelvis (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	68.9	70.4	72.9	76.4	76.9	77.1	76.4	77.9	77.9	79.7	81.3	79.7	81.7	85.0	83.9	85.0	86.3	85.2	86.5	86.4	85.7	87.0
2-year	60.3	61.7	65.0	69.2	69.7	70.4	70.0	71.1	71.7	73.8	73.9	74.7	76.1	79.7	80.1	81.7	82.4	81.2	82.1	81.4	80.6	
3-year	56.3	57.0	60.8	65.8	65.5	67.3	66.0	67.3	67.5	69.3	70.8	71.2	73.2	76.3	77.6	78.4	80.2	78.9	79.2	79.0		
4-year	53.0	53.9	57.8	63.2	63.3	64.2	63.6	64.4	64.5	67.4	68.1	69.0	71.1	73.3	75.9	75.7	77.5	76.3	77.2			
5-year	50.9	52.0	55.8	60.7	61.4	62.5	61.7	63.2	62.4	65.4	66.4	67.5	68.9	71.1	74.4	73.7	74.9	74.3				
6-year	49.3	49.7	53.8	59.1	59.4	60.5	59.7	61.2	60.4	63.9	64.9	65.4	67.8	69.2	72.9	72.2	73.4					
7-year	47.4	48.5	52.2	57.4	58.1	58.9	57.9	59.4	59.0	62.3	63.0	63.5	66.1	67.8	71.8	70.6						
8-year	46.2	47.3	51.0	56.1	56.9	58.5	55.8	57.9	57.3	60.1	61.8	61.7	64.6	65.7	70.8							
9-year	45.0	46.0	49.6	55.0	55.4	57.8	53.9	56.6	55.7	58.8	60.7	60.3	63.2	63.9								
10-year	44.0	44.9	47.9	53.2	54.3	55.9	53.0	55.4	53.8	56.8	59.4	59.2	62.1									
11-year	43.1	43.6	46.5	51.7	52.3	55.0	51.9	54.9	52.7	55.7	57.3	58.3										
12-year	42.2	42.7	45.3	50.6	50.7	53.5	51.1	54.2	51.7	54.9	56.1											
13-year	41.5	41.9	44.3	49.4	49.2	51.7	50.1	53.4	51.0	54.0												
14-year	40.5	41.3	43.0	48.1	48.2	50.3	49.5	52.0	49.6													
15-year	39.5	40.9	42.1	47.4	47.2	48.9	48.5	50.6														
16-year	39.2	40.3	41.0	46.7	46.9	48.0	47.1															
17-year	38.7	39.7	40.1	45.9	45.7	47.8																
18-year	37.6	39.2	39.2	44.9	44.5																	
19-year	36.6	38.2	38.4	44.1																		
20-year	36.0	37.2	37.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 11.10  
Cancer of the Kidney and Renal Pelvis (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	69.5	70.5	73.3	77.4	79.1	78.0	78.1	78.5	77.4	79.2	80.6	80.1	80.6	85.5	84.1	84.8	86.2	85.1	86.3	86.5	85.9	86.8
2-year	60.7	61.9	65.5	69.5	71.3	71.7	70.9	72.0	70.8	72.7	73.5	75.0	75.7	80.5	80.6	81.3	82.2	80.6	81.7	80.6	80.7	
3-year	56.4	57.4	61.4	66.2	67.1	68.0	66.7	67.9	66.8	67.9	70.2	70.8	73.3	77.1	77.9	77.8	79.5	78.1	78.7	78.0		
4-year	52.9	54.4	58.3	63.5	64.4	64.8	64.2	64.9	63.4	65.7	67.5	68.3	70.7	74.7	75.7	74.7	76.4	75.4	76.9			
5-year	51.0	52.4	56.2	60.8	62.4	63.1	61.7	63.7	61.4	62.8	65.6	67.2	69.0	72.0	74.1	72.7	73.4	73.1				
6-year	49.5	50.1	53.9	59.0	59.5	61.8	59.4	61.3	58.7	61.5	63.6	65.1	68.1	69.7	71.9	70.6	72.1					
7-year	47.3	48.9	52.1	57.4	58.5	60.1	57.4	59.3	57.6	59.6	60.9	63.3	66.1	67.9	70.7	68.7						
8-year	45.8	47.7	50.7	56.1	57.2	59.2	54.4	57.2	55.6	57.5	59.6	61.5	64.4	66.1	69.3							
9-year	44.8	46.3	48.8	55.1	56.0	58.7	52.5	56.3	53.6	55.9	58.8	60.3	63.0	64.1								
10-year	43.4	45.2	47.5	53.4	54.7	56.3	52.1	55.2	51.5	54.2	57.3	59.1	62.0									
11-year	42.4	44.0	45.5	51.9	53.3	55.5	50.4	54.5	50.1	53.1	55.6	58.1										
12-year	41.3	43.1	44.0	50.8	50.9	53.7	49.2	53.2	49.2	52.8	54.5											
13-year	40.6	42.5	42.8	49.6	49.2	52.3	48.6	52.9	48.9	52.0												
14-year	39.5	41.4	41.6	48.4	49.1	50.5	48.1	51.9	47.9													
15-year	38.4	41.1	40.8	47.6	47.6	48.5	46.4	50.1														
16-year	38.0	40.3	39.5	47.1	47.6	47.2	45.0															
17-year	37.5	39.9	38.7	46.3	46.3	47.0																
18-year	36.5	39.4	37.6	45.1	44.8																	
19-year	35.5	38.5	36.8	44.3																		
20-year	34.7	37.3	36.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 11.11  
Cancer of the Kidney and Renal Pelvis (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	67.8	70.3	72.3	74.7	73.4	75.7	73.8	76.8	78.6	80.6	82.4	79.0	83.5	84.2	83.6	85.3	86.4	85.3	86.7	86.2	85.4	87.4
2-year	59.6	61.5	64.2	68.7	67.2	68.5	68.7	69.5	73.2	75.6	74.6	74.2	76.6	78.4	79.1	82.3	82.7	82.1	82.8	82.7	80.5	
3-year	56.1	56.4	59.7	65.1	62.9	66.1	64.9	66.4	68.7	71.7	71.8	71.9	73.1	75.2	77.2	79.3	81.4	80.2	80.0	80.7		
4-year	53.0	53.2	57.0	62.7	61.5	63.3	62.7	63.6	66.1	70.2	69.1	70.1	71.7	71.2	76.2	77.3	79.3	77.6	77.8			
5-year	50.6	51.3	55.0	60.5	59.8	61.6	61.4	62.3	64.0	69.7	67.7	68.0	68.6	69.7	75.0	75.1	77.3	76.1				
6-year	49.0	49.0	53.7	59.1	58.9	58.5	60.1	60.9	63.0	67.7	66.9	65.8	67.4	68.4	74.3	74.4	75.4					
7-year	47.7	47.9	52.4	57.5	57.3	57.1	58.6	59.4	61.1	66.5	66.2	63.8	66.0	67.5	73.6	73.4						
8-year	46.9	46.8	51.5	56.1	56.3	57.1	57.7	58.6	59.8	64.3	65.4	62.1	65.0	65.1	73.2							
9-year	45.2	45.5	50.7	54.8	54.1	56.4	56.0	56.9	58.8	63.6	63.8	60.2	63.6	63.5								
10-year	44.9	44.3	48.6	52.9	53.7	55.2	54.3	55.8	57.5	61.0	62.6	59.2	62.2									
11-year	44.2	42.8	47.9	51.4	50.8	54.1	53.9	55.4	56.6	60.0	60.2	58.5										
12-year	43.5	41.9	47.1	50.3	50.2	53.0	53.9	55.4	55.7	58.4	58.6											
13-year	43.0	41.0	46.4	49.2	49.0	50.9	52.4	54.0	54.4	57.2												
14-year	42.1	40.6	45.0	47.8	46.8	49.5	51.5	52.1	52.2													
15-year	41.2	40.3	43.9	46.9	46.1	49.1	51.5	51.0														
16-year	41.0	40.2	43.3	46.1	45.0	48.9	50.2															
17-year	40.4	39.3	42.2	45.4	44.6	48.9																
18-year	39.3	38.7	41.5	44.6	44.1																	
19-year	38.4	37.6	40.8	43.8																		
20-year	38.1	37.1	40.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 12.9  
Cancer of the Larynx (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	88.2	88.5	88.2	87.8	89.1	88.3	85.9	86.2	85.4	85.4	85.3	84.2	84.1	85.6	86.7	86.4	88.1	84.1	86.9	85.6	86.8	87.7
2-year	79.1	79.5	79.0	78.0	80.0	79.2	77.3	75.9	74.7	76.8	75.5	74.8	74.7	75.4	78.0	74.6	75.5	76.3	76.9	76.9	72.3	
3-year	73.3	74.0	73.6	71.7	74.8	74.1	72.1	70.8	70.7	71.0	70.0	70.0	66.8	68.6	72.5	68.5	70.5	71.1	71.5	70.0		
4-year	68.8	70.0	68.7	67.3	69.3	69.7	68.7	67.0	68.6	66.7	66.5	67.0	62.6	64.2	69.9	62.8	65.7	66.6	67.9			
5-year	65.5	66.8	65.9	64.5	66.1	65.8	65.4	63.5	63.7	63.3	62.9	62.7	60.4	62.2	65.8	59.6	61.9	64.1				
6-year	63.1	63.9	62.5	61.0	63.2	63.6	62.2	59.1	60.6	60.4	60.6	60.1	56.1	59.5	61.4	56.9	59.2					
7-year	60.8	61.3	60.0	59.2	59.8	61.3	59.6	55.5	57.3	56.5	57.2	56.3	54.2	57.0	58.4	54.0						
8-year	58.8	59.6	57.1	56.4	57.4	57.9	57.0	52.8	54.1	53.0	54.4	52.7	51.9	53.8	54.9							
9-year	56.4	57.3	54.5	53.9	54.3	54.2	55.5	50.3	52.2	50.7	52.0	52.2	49.4	51.8								
10-year	54.1	55.4	52.1	51.3	51.1	52.0	53.3	48.4	50.4	48.9	50.4	48.6	47.3									
11-year	52.7	52.9	50.1	49.3	47.8	49.3	50.9	47.1	47.6	47.5	47.0	45.4										
12-year	50.9	50.2	48.0	47.4	46.0	46.7	46.2	45.0	45.2	44.3	45.2											
13-year	49.6	48.0	46.9	45.0	44.2	44.7	44.9	43.2	42.3	43.0												
14-year	48.0	46.5	44.2	43.1	41.3	41.6	43.0	41.6	41.2													
15-year	45.8	44.8	41.8	41.3	38.8	38.8	42.0	39.5														
16-year	43.6	42.1	40.2	39.4	37.9	37.3	40.8															
17-year	41.4	40.6	38.7	37.5	37.2	35.3																
18-year	40.2	38.8	37.2	35.4	36.1																	
19-year	38.2	37.2	34.6	33.5																		
20-year	36.4	35.4	33.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 12.10  
Cancer of the Larynx (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	88.5	88.6	88.5	88.5	91.2	88.1	88.4	87.2	86.7	85.4	85.7	84.8	84.1	86.2	86.5	86.7	88.9	84.3	87.6	86.1	87.0	86.6
2-year	79.2	79.7	79.4	79.1	81.8	79.3	80.0	76.7	75.9	77.4	75.7	75.1	75.3	75.5	77.1	75.4	75.6	76.9	77.3	77.6	72.3	
3-year	73.5	74.5	74.2	72.6	76.5	74.3	74.8	71.6	71.6	71.7	70.9	71.0	68.4	68.7	72.5	69.5	70.1	72.8	71.5	71.0		
4-year	69.2	70.6	69.5	68.3	71.5	69.7	71.2	68.3	69.6	67.3	66.7	68.3	63.3	63.6	70.0	64.0	65.8	67.8	67.4			
5-year	65.8	67.3	66.6	65.6	68.2	66.4	68.2	65.6	65.3	64.2	63.1	63.6	60.5	61.8	65.4	61.6	61.5	65.3				
6-year	63.5	64.5	63.2	62.1	65.4	64.0	65.1	62.3	62.0	61.6	60.8	61.1	56.2	59.9	60.8	58.4	58.9					
7-year	61.3	61.8	61.0	60.4	61.9	61.4	62.9	58.7	58.6	58.5	58.7	57.1	54.5	58.2	57.3	55.4						
8-year	59.1	60.4	58.2	57.8	59.4	57.9	59.7	55.6	55.5	55.7	56.1	53.9	53.1	55.4	53.0							
9-year	56.7	58.0	56.1	55.3	56.6	53.9	57.8	53.0	53.3	53.9	54.4	53.0	50.5	53.4								
10-year	54.7	56.3	53.9	52.6	53.7	51.6	55.8	50.8	51.2	51.8	53.0	49.5	48.8									
11-year	53.5	53.7	52.1	50.6	50.0	49.1	53.8	50.1	48.5	49.8	49.1	46.5										
12-year	52.0	51.0	50.1	48.7	49.1	46.2	48.8	48.7	46.1	47.0	47.4											
13-year	50.8	48.8	49.2	46.5	47.2	44.0	47.0	46.5	43.9	46.4												
14-year	49.1	47.0	46.8	44.5	44.8	41.8	44.7	45.6	42.5													
15-year	46.9	45.2	44.3	42.7	41.8	39.3	44.3	43.5														
16-year	44.7	42.9	42.7	40.8	40.6	37.6	43.3															
17-year	42.5	41.7	41.3	39.1	39.9	35.4																
18-year	41.2	39.8	39.5	37.0	39.6																	
19-year	39.0	38.2	36.6	34.9																		
20-year	37.5	36.3	35.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 12.11  
Cancer of the Larynx (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	86.8	88.1	86.9	85.2	80.1	88.8	76.7	83.1	81.1	85.4	83.2	81.7	83.8	83.5	87.6	85.2	84.8	83.2	83.1	83.2	85.8	91.9
2-year	78.6	78.6	77.3	73.6	72.0	79.0	67.1	73.4	70.7	74.3	74.3	73.4	71.8	74.9	81.0	70.6	74.9	73.5	74.3	73.6	72.4	
3-year	71.7	72.0	71.1	68.3	67.5	73.4	62.0	68.3	67.1	68.1	66.0	65.9	59.9	68.1	72.5	64.0	71.9	63.4	72.0	65.2		
4-year	67.0	67.5	65.6	63.2	60.1	69.4	59.2	62.9	65.0	63.9	65.5	61.5	59.6	65.8	69.6	57.1	65.3	61.2	70.4			
5-year	63.8	64.2	62.6	60.0	57.4	63.6	55.4	57.1	58.3	59.7	61.7	59.1	58.5	63.2	67.1	50.6	62.9	58.5				
6-year	61.1	61.2	59.3	56.4	53.8	62.3	51.8	49.6	55.5	55.8	59.2	55.4	55.4	57.4	63.8	49.8	60.5					
7-year	58.4	58.9	56.1	54.2	51.4	60.0	48.0	45.6	52.8	48.3	50.2	52.9	52.7	52.3	62.3	46.8						
8-year	57.1	56.3	52.5	50.8	49.1	57.8	46.7	44.0	49.5	41.7	46.7	48.1	46.8	48.4	61.2							
9-year	54.4	54.2	48.2	48.4	45.1	55.0	46.7	41.8	48.1	38.0	41.3	48.1	44.6	46.1								
10-year	51.2	51.6	45.2	46.3	40.9	53.0	44.2	40.5	47.4	37.1	38.3	44.9	40.7									
11-year	48.4	49.2	42.4	44.3	38.8	50.1	39.8	37.6	44.1	37.1	37.5	40.5										
12-year	45.7	46.8	39.8	42.2	34.0	48.4	36.7	34.3	41.8	33.5	34.8											
13-year	44.1	44.4	38.0	39.1	32.4	45.9	36.7	33.3	37.0	30.0												
14-year	42.7	43.4	34.3	37.3	28.2	40.4	36.0	29.7	36.6													
15-year	40.5	42.7	32.6	35.8	27.0	36.9	33.7	27.9														
16-year	38.6	39.0	30.8	33.9	27.0	36.3	31.9															
17-year	36.1	35.7	29.3	31.4	26.3	34.6																
18-year	35.3	34.7	28.9	29.5	22.7																	
19-year	34.1	33.2	27.1	28.3																		
20-year	31.7	31.8	25.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 13.17  
LeukemiaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	60.8	62.6	64.8	66.8	68.0	68.1	67.8	66.5	65.9	66.8	70.5	72.0	73.0	74.8	73.9	76.1	76.5	76.2	76.9	77.6	78.5	78.1
2-year	50.1	52.5	55.3	57.4	58.8	59.8	59.7	57.8	58.2	58.8	62.8	64.6	65.9	67.4	68.1	70.0	70.1	69.7	70.1	71.6	71.8	
3-year	43.7	46.5	49.6	52.7	54.1	55.2	54.8	53.8	54.6	54.9	58.7	61.6	62.0	63.9	64.4	66.7	66.9	65.9	67.5	68.0		
4-year	38.8	41.7	45.5	49.0	50.6	51.7	50.8	50.0	51.5	51.7	56.5	59.3	59.1	61.5	62.3	63.9	64.5	63.2	64.7			
5-year	34.6	37.6	42.3	46.0	48.0	48.5	48.2	47.9	48.2	49.6	54.0	57.4	57.0	59.2	60.6	61.8	62.9	61.0				
6-year	31.4	35.0	39.9	43.5	45.6	46.3	45.6	45.8	46.1	48.2	52.1	55.6	55.1	56.7	58.8	59.7	61.2					
7-year	29.1	32.5	37.1	40.9	44.1	44.9	43.7	44.2	44.3	47.0	50.7	53.9	53.0	55.5	57.3	57.9						
8-year	27.0	30.3	34.9	38.7	41.5	43.6	43.0	42.8	42.8	45.4	49.2	53.0	51.2	54.0	55.4							
9-year	25.0	28.5	32.9	37.2	40.4	41.8	41.7	41.7	41.9	44.5	47.9	51.3	50.0	52.3								
10-year	23.7	26.9	31.6	35.9	38.8	40.4	40.4	40.6	40.4	43.4	46.7	49.8	48.0									
11-year	22.4	25.7	29.9	34.6	37.6	39.6	38.6	39.3	39.0	42.1	45.4	48.4										
12-year	21.2	24.5	28.8	33.5	36.9	38.4	37.5	38.5	38.1	41.4	44.3											
13-year	20.4	23.6	27.9	32.5	36.5	37.9	36.8	37.4	37.0	39.9												
14-year	19.7	22.9	27.2	31.7	35.4	36.8	36.6	36.4	36.5													
15-year	19.2	22.2	26.7	31.2	35.0	35.7	36.0	35.2														
16-year	18.5	21.4	26.0	30.5	34.7	35.5	35.9															
17-year	18.0	20.6	25.6	29.8	33.7	35.0																
18-year	17.6	20.1	25.2	29.3	32.6																	
19-year	17.1	19.4	24.7	28.9																		
20-year	16.6	19.0	24.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 13.18  
LeukemiaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	60.4	62.8	65.5	67.9	69.2	69.6	68.7	66.6	66.7	68.6	72.7	72.9	74.0	76.5	75.9	76.6	77.7	76.9	78.6	78.6	79.8	78.8
2-year	49.4	52.4	56.1	58.2	60.4	61.5	60.9	58.3	58.9	60.6	64.6	64.9	66.6	68.4	69.9	70.1	71.4	70.8	71.9	73.1	73.3	
3-year	42.7	46.0	49.9	53.1	55.5	57.2	55.0	54.4	55.1	56.9	60.5	62.0	62.4	65.0	66.2	66.7	68.4	67.0	69.0	70.0		
4-year	37.7	41.1	45.9	49.4	51.6	53.3	50.4	50.3	51.8	53.5	57.8	59.3	59.7	62.3	64.7	64.0	66.1	64.1	66.6			
5-year	33.4	37.1	42.9	46.1	48.1	49.4	47.6	48.2	47.8	51.9	54.9	56.8	57.3	59.8	62.6	61.7	64.5	62.2				
6-year	30.3	34.3	40.4	43.5	45.1	47.0	45.7	45.8	45.9	50.4	52.5	54.8	55.1	57.0	60.4	59.2	62.6					
7-year	27.7	31.8	37.3	40.8	43.8	45.6	43.6	44.1	43.7	49.3	51.0	52.5	52.9	55.9	58.9	57.6						
8-year	25.4	29.4	35.3	38.4	41.6	44.4	42.8	42.7	42.0	47.2	49.5	51.3	50.7	54.4	56.6							
9-year	23.2	27.5	33.2	37.0	40.3	42.2	41.8	41.6	41.2	45.8	48.1	50.0	49.3	52.0								
10-year	21.9	26.0	31.6	35.7	38.2	40.5	41.0	40.6	39.7	44.8	46.7	48.2	47.0									
11-year	20.5	24.9	30.2	34.5	37.6	39.6	38.8	38.9	38.0	43.7	45.4	46.5										
12-year	19.3	24.2	29.0	33.3	37.0	38.8	37.7	38.0	37.2	43.0	44.5											
13-year	18.6	23.4	28.3	32.4	36.6	38.6	37.1	36.4	35.9	41.3												
14-year	17.9	22.7	27.7	31.3	35.6	37.5	36.7	35.4	35.3													
15-year	17.4	22.1	26.9	30.8	35.1	36.7	36.2	34.4														
16-year	16.8	21.2	26.3	30.2	34.6	36.4	35.8															
17-year	16.4	20.4	25.9	29.5	33.7	36.1																
18-year	15.9	19.9	25.6	28.8	32.2																	
19-year	15.4	19.2	25.3	28.6																		
20-year	14.6	18.7	24.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 13.19  
LeukemiaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	61.3	62.3	63.8	65.5	66.4	66.2	66.6	66.5	64.6	64.3	67.4	70.8	71.6	72.6	71.2	75.5	75.0	75.2	74.5	76.3	76.7	77.2
2-year	50.9	52.7	54.2	56.4	56.7	57.5	58.0	57.1	57.3	56.4	60.5	64.3	64.9	66.1	65.6	69.9	68.3	68.2	67.6	69.6	69.7	
3-year	45.1	47.1	49.2	52.2	52.3	52.7	54.4	53.1	53.9	52.1	56.3	60.9	61.4	62.4	61.8	66.6	65.0	64.3	65.4	65.4		
4-year	40.2	42.4	44.9	48.5	49.2	49.6	51.4	49.6	51.1	49.3	54.7	59.2	58.2	60.3	58.9	63.8	62.4	62.0	62.1			
5-year	36.1	38.3	41.4	45.8	47.8	47.2	48.9	47.5	48.9	46.5	52.8	58.1	56.5	58.3	57.6	61.9	60.6	59.5				
6-year	32.8	36.0	39.2	43.5	46.1	45.4	45.6	45.7	46.3	45.4	51.4	56.4	55.0	56.2	56.5	60.3	59.1					
7-year	31.0	33.4	36.7	40.9	44.4	44.0	43.8	44.4	45.0	43.7	50.3	55.8	53.2	54.8	54.9	58.3						
8-year	29.0	31.5	34.4	39.0	41.3	42.6	43.3	42.8	43.8	42.7	48.8	55.2	51.9	53.4	53.6							
9-year	27.3	29.9	32.6	37.5	40.6	41.3	41.3	41.9	42.9	42.7	47.5	53.0	50.8	52.6								
10-year	25.9	28.1	31.5	36.2	39.6	40.2	39.6	40.4	41.4	41.5	46.5	51.7	49.4									
11-year	24.8	26.8	29.4	34.6	37.5	39.5	38.2	39.7	40.3	40.0	45.2	50.9										
12-year	23.5	24.9	28.4	33.7	36.8	37.9	37.2	39.1	39.3	39.4	44.1											
13-year	22.8	23.8	27.5	32.8	36.1	36.9	36.5	38.5	38.5	38.0												
14-year	22.1	23.1	26.6	32.1	35.1	35.8	36.2	37.8	37.9													
15-year	21.4	22.4	26.3	31.7	34.9	34.4	35.8	36.1														
16-year	20.7	21.6	25.7	30.9	34.9	34.1	35.8															
17-year	20.2	20.9	25.1	30.3	33.7	33.5																
18-year	19.8	20.4	24.7	29.9	33.0																	
19-year	19.3	19.7	24.0	29.4																		
20-year	19.0	19.4	23.7																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 14.9  
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	13.9	14.9	17.7	21.5	23.0	24.7	27.8	26.9	27.7	29.0	31.2	32.8	36.0	38.2	39.3	39.6	42.0	45.1	44.6	48.3	46.5	46.0
2-year	6.6	8.3	9.8	12.4	13.6	15.0	17.4	17.0	17.7	20.0	21.6	22.2	24.6	26.1	27.0	28.8	30.3	32.6	31.2	35.7	32.9	
3-year	4.8	6.0	7.3	8.7	9.5	10.8	12.4	13.1	14.3	15.4	15.9	17.3	20.3	20.6	21.3	23.4	23.9	25.7	24.1	27.5		
4-year	4.1	4.6	6.3	6.9	6.9	9.1	10.1	10.7	12.0	12.4	13.7	15.4	16.9	17.5	18.4	19.8	20.9	21.5	19.5			
5-year	3.4	3.8	5.4	5.6	5.7	8.1	8.1	9.4	10.1	11.7	11.9	14.0	15.4	14.5	16.8	17.0	18.4	18.5				
6-year	3.0	3.5	5.0	5.0	4.9	7.0	7.4	8.4	9.0	10.8	10.9	11.9	14.7	13.3	15.4	15.4	16.4					
7-year	2.8	3.1	4.8	4.6	4.4	6.6	6.6	6.9	8.3	10.0	9.8	11.3	13.0	12.6	14.0	14.4						
8-year	2.7	2.9	4.4	4.4	4.2	6.4	5.8	6.6	7.8	9.7	8.8	10.3	12.0	11.9	13.5							
9-year	2.6	2.8	4.2	4.3	4.1	5.9	5.6	5.6	7.5	9.4	8.4	10.0	11.4	11.3								
10-year	2.6	2.8	4.0	4.2	3.6	5.6	5.4	5.5	7.4	9.0	7.8	9.1	10.8									
11-year	2.6	2.6	4.0	4.0	3.2	5.5	5.4	4.8	6.9	8.7	7.7	8.7										
12-year	2.5	2.6	3.8	3.9	3.1	5.2	5.4	4.6	6.8	8.6	7.5											
13-year	2.3	2.4	3.8	3.8	3.1	5.0	5.4	4.5	6.6	8.4												
14-year	2.3	2.4	3.7	3.7	3.1	4.8	5.4	4.5	6.1													
15-year	2.2	2.4	3.7	3.7	3.0	3.9	5.0	4.5														
16-year	2.2	2.3	3.7	3.6	3.0	3.8	4.7															
17-year	2.1	2.3	3.7	3.5	2.9	3.8																
18-year	2.0	2.2	3.7	3.4	2.7																	
19-year	2.0	2.1	3.7	3.3																		
20-year	2.0	2.1	3.7																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 14.10  
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	11.4	12.9	14.8	20.2	21.3	24.8	26.8	25.6	28.8	28.4	30.7	32.1	35.0	37.4	40.2	39.9	41.1	45.7	45.4	49.1	46.4	45.8
2-year	4.8	6.5	7.4	11.4	12.1	15.9	16.5	16.1	17.6	19.3	20.4	21.1	24.6	25.5	27.8	29.7	29.6	33.0	31.9	36.6	33.1	
3-year	3.2	4.9	5.2	8.1	8.9	11.2	12.0	12.0	13.7	15.5	15.1	17.6	20.0	19.9	21.7	23.8	24.0	26.0	24.4	28.7		
4-year	2.7	3.4	4.5	6.3	6.2	9.2	9.6	10.6	11.4	12.3	12.8	15.6	16.7	17.4	18.6	20.0	20.3	21.8	19.6			
5-year	2.0	2.8	3.6	5.2	5.0	7.8	7.9	8.9	10.1	11.3	11.0	14.2	15.6	14.3	17.0	17.0	18.0	18.8				
6-year	1.7	2.6	3.3	4.8	4.2	6.8	7.3	7.6	8.9	10.5	10.1	11.9	14.8	13.0	15.6	15.4	15.9					
7-year	1.4	2.2	3.3	4.3	3.7	6.5	6.7	6.2	8.3	10.0	9.1	11.1	13.2	12.2	13.9	14.4						
8-year	1.4	1.9	3.0	4.1	3.5	6.3	5.5	6.1	7.7	9.9	7.9	9.9	11.9	11.6	13.2							
9-year	1.3	1.9	3.0	3.9	3.4	5.9	5.4	5.2	7.5	9.8	7.4	9.4	11.3	11.2								
10-year	1.3	1.9	2.9	3.8	2.7	5.4	5.4	5.2	7.3	9.5	7.0	8.4	10.4									
11-year	1.3	1.8	2.9	3.7	2.3	5.2	5.4	4.4	6.9	9.2	7.0	7.8										
12-year	1.3	1.7	2.7	3.6	2.1	4.9	5.4	4.3	6.9	9.1	6.8											
13-year	1.1	1.4	2.7	3.5	2.1	4.8	5.4	4.3	6.8	8.7												
14-year	1.1	1.4	2.6	3.5	2.1	4.4	5.3	4.2	6.3													
15-year	1.0	1.4	2.6	3.5	2.1	3.8	5.0	4.2														
16-year	1.0	1.4	2.6	3.4	2.1	3.8	4.4															
17-year	1.0	1.4	2.6	3.4	2.1	3.8																
18-year	1.0	1.4	2.6	3.3	2.1																	
19-year	1.0	1.4	2.6	3.2																		
20-year	1.0	1.4	2.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 14.11  
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	18.7	18.9	23.6	24.2	26.3	24.6	29.7	29.7	25.4	30.2	32.3	34.5	38.5	40.5	37.2	38.7	44.6	43.5	42.4	46.1	46.7	46.5
2-year	9.9	11.8	14.5	14.4	16.5	13.2	19.3	18.7	17.9	21.5	24.4	24.7	24.5	27.8	25.1	26.3	32.1	31.6	29.3	33.4	32.5	
3-year	7.8	8.2	11.4	10.1	10.4	9.9	13.3	15.2	15.3	15.3	17.7	16.6	21.2	22.7	20.3	22.3	23.5	24.9	23.3	24.0		
4-year	6.6	6.7	9.9	8.1	8.3	8.7	11.0	10.8	13.3	12.6	15.9	14.9	17.3	17.9	17.8	19.3	22.5	20.7	19.2			
5-year	6.1	5.6	8.8	6.4	7.0	8.5	8.4	10.2	10.3	12.3	14.0	13.3	14.9	15.1	16.3	17.2	19.5	17.8				
6-year	5.4	5.1	8.4	5.6	6.0	7.3	7.3	9.9	9.2	11.3	12.7	11.8	14.5	14.0	14.9	15.4	17.9					
7-year	5.4	4.7	7.7	5.1	5.7	6.7	6.2	8.4	8.2	10.0	11.3	11.6	12.6	13.5	14.0	14.4						
8-year	5.2	4.6	7.0	5.1	5.4	6.4	6.2	7.5	8.0	9.2	10.7	11.1	12.1	12.7	14.0							
9-year	4.9	4.5	6.6	5.0	5.4	5.9	5.8	6.2	7.4	8.4	10.6	11.1	11.6	11.5								
10-year	4.9	4.4	6.2	5.0	5.1	5.9	5.2	5.9	7.4	8.1	9.4	10.8	11.6									
11-year	4.9	4.3	6.0	4.5	4.8	5.9	5.2	5.6	6.9	7.6	9.2	10.6										
12-year	4.5	4.3	5.9	4.4	4.8	5.7	5.2	5.3	6.3	7.6	9.0											
13-year	4.4	4.2	5.8	4.4	4.8	5.4	5.2	5.0	6.0	7.6												
14-year	4.4	4.2	5.8	4.2	4.8	5.4	5.2	5.0	5.3													
15-year	4.4	4.2	5.8	4.0	4.4	4.3	5.0	5.0														
16-year	4.3	4.1	5.8	4.0	4.4	3.9	5.0															
17-year	4.0	3.9	5.8	3.8	4.0	3.9																
18-year	3.8	3.6	5.7	3.6	3.5																	
19-year	3.8	3.3	5.7	3.5																		
20-year	3.8	3.3	5.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 15.15  
Cancer of the Lung and Bronchus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	35.3	37.2	38.5	39.5	40.3	39.9	40.4	39.9	41.4	40.9	40.2	40.7	41.9	42.2	43.5	44.0	44.4	45.2	45.8	44.8	46.6	45.5
2-year	21.1	22.0	22.6	23.7	24.9	24.7	24.7	25.2	25.8	25.8	25.5	26.5	26.5	27.7	28.4	29.4	30.1	31.0	31.4	31.0	32.5	
3-year	16.3	16.9	17.1	18.3	19.1	19.3	19.3	19.8	19.8	20.2	19.8	20.7	20.7	22.3	22.6	23.5	23.9	24.7	25.2	24.7		
4-year	13.9	14.5	14.6	15.5	16.5	16.2	16.6	17.0	17.0	17.5	16.8	17.5	17.9	18.8	19.5	20.0	20.5	21.3	21.5			
5-year	12.5	12.9	13.0	13.8	14.5	14.5	14.7	14.6	15.1	15.7	14.9	15.5	16.0	16.8	17.4	17.5	18.3	18.7				
6-year	11.4	11.7	11.9	12.6	13.2	13.2	13.3	13.3	13.7	14.2	13.4	14.1	14.5	15.4	15.7	16.2	16.7					
7-year	10.7	10.8	10.9	11.6	12.3	12.1	12.2	12.2	12.7	12.9	12.3	12.9	13.3	14.1	14.5	15.0						
8-year	10.0	10.0	10.1	10.7	11.4	11.2	11.3	11.2	11.8	12.0	11.4	11.8	12.0	13.1	13.4							
9-year	9.4	9.2	9.4	9.9	10.7	10.3	10.4	10.5	11.0	11.2	10.6	11.0	11.1	12.4								
10-year	8.8	8.6	8.8	9.2	10.0	9.4	9.8	10.0	10.5	10.4	10.0	10.3	10.2									
11-year	8.3	8.1	8.2	8.6	9.4	8.8	9.1	9.4	9.7	9.7	9.3	9.4										
12-year	7.8	7.7	7.7	8.0	8.8	8.2	8.4	8.9	9.1	9.0	8.7											
13-year	7.4	7.2	7.2	7.5	8.2	7.9	7.9	8.1	8.5	8.5												
14-year	7.1	6.8	6.8	7.1	7.6	7.5	7.5	7.6	7.9													
15-year	6.6	6.4	6.4	6.7	7.2	7.0	7.1	7.1														
16-year	6.3	6.0	6.1	6.2	6.9	6.6	6.5															
17-year	6.0	5.6	5.7	5.9	6.4	6.3																
18-year	5.7	5.3	5.3	5.5	5.9																	
19-year	5.4	4.9	4.9	5.1																		
20-year	5.1	4.6	4.7																			
21-year	4.9	4.3	4.5																			
22-year	4.6	4.1	4.2																			
23-year	4.4	3.8	4.0																			
24-year	4.2	3.6	3.8																			
25-year	4.0	3.4																				
26-year	3.8	3.2																				
27-year	3.6	3.0																				
28-year	3.5	2.9																				
29-year	3.3	2.7																				
30-year	3.1																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 15.16  
Cancer of the Lung and Bronchus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	33.4	35.4	36.5	37.2	38.0	38.0	38.0	37.0	38.2	38.7	37.0	37.1	39.4	39.0	40.0	41.3	40.9	42.0	42.7	41.1	42.3	41.4
2-year	19.5	20.2	21.0	21.6	23.1	23.0	23.0	22.6	22.7	23.7	22.2	23.1	23.7	24.7	24.8	26.8	26.2	27.8	27.6	27.2	28.3	
3-year	14.8	15.3	15.6	16.3	17.4	17.8	17.7	17.4	16.7	18.2	17.2	17.9	18.2	19.5	19.5	20.8	20.8	22.1	21.8	21.4		
4-year	12.5	12.9	13.1	13.6	14.8	14.6	15.0	14.7	14.1	15.5	14.3	15.0	15.5	16.6	16.6	17.3	17.5	18.9	18.3			
5-year	11.1	11.4	11.6	12.1	13.2	13.1	13.3	12.4	12.5	14.0	12.7	13.5	14.0	14.9	14.9	15.1	15.6	16.7				
6-year	10.1	10.3	10.6	11.0	11.8	11.7	11.9	11.0	11.2	12.6	11.5	12.1	12.6	13.5	13.2	13.9	14.2					
7-year	9.4	9.5	9.7	10.0	11.2	10.6	10.8	10.1	10.3	11.3	10.4	11.1	11.6	12.2	12.1	12.8						
8-year	8.8	8.6	9.0	9.1	10.2	9.8	10.0	9.1	9.5	10.6	9.5	10.0	10.8	11.4	11.2							
9-year	8.2	7.9	8.4	8.4	9.6	9.1	9.1	8.5	8.7	9.9	8.9	9.3	9.8	10.8								
10-year	7.7	7.4	7.9	7.9	8.8	8.2	8.6	8.0	8.3	9.1	8.3	8.6	8.9									
11-year	7.2	7.0	7.3	7.2	8.3	7.4	7.9	7.5	7.7	8.3	7.7	7.9										
12-year	6.7	6.6	6.8	6.7	8.0	6.9	7.2	7.0	7.2	7.7	7.2											
13-year	6.3	6.2	6.3	6.2	7.2	6.7	6.8	6.3	6.8	7.2												
14-year	6.0	5.8	6.0	5.8	6.9	6.3	6.4	5.9	6.3													
15-year	5.6	5.4	5.6	5.5	6.4	5.8	6.0	5.6														
16-year	5.3	5.0	5.3	5.1	6.2	5.4	5.7															
17-year	5.1	4.6	4.8	4.8	5.7	5.2																
18-year	4.7	4.4	4.5	4.5	5.2																	
19-year	4.5	4.1	4.1	4.2																		
20-year	4.2	3.7	3.9																			
21-year	4.1	3.5	3.6																			
22-year	3.9	3.3	3.4																			
23-year	3.7	3.1	3.2																			
24-year	3.4	2.8	3.0																			
25-year	3.3	2.7																				
26-year	3.1	2.5																				
27-year	2.8	2.4																				
28-year	2.8	2.3																				
29-year	2.7	2.1																				
30-year	2.6																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 15.17  
Cancer of the Lung and Bronchus (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	40.4	41.3	42.2	42.8	43.5	42.4	43.3	43.6	45.4	43.6	44.2	45.0	44.9	45.8	47.3	47.1	48.2	48.8	49.1	48.8	51.2	50.1
2-year	25.3	25.7	25.5	26.7	27.4	26.9	26.9	28.4	29.5	28.5	29.7	30.5	29.9	31.1	32.3	32.4	34.3	34.5	35.5	35.1	37.0	
3-year	20.2	20.5	19.7	21.1	21.6	21.4	21.3	22.9	23.6	22.8	22.9	24.0	23.8	25.4	26.0	26.6	27.3	27.7	28.8	28.3		
4-year	17.7	17.8	17.2	18.3	18.8	18.3	18.5	19.9	20.5	19.9	19.8	20.4	20.6	21.4	22.7	22.9	23.7	23.9	24.9			
5-year	16.1	16.0	15.4	16.4	16.4	16.5	16.5	17.4	18.3	17.7	17.7	17.9	18.3	18.9	20.1	20.3	21.1	21.0				
6-year	14.9	14.6	14.1	15.1	15.0	15.1	15.1	16.1	16.7	16.1	15.8	16.4	16.7	17.5	18.4	18.7	19.5					
7-year	14.0	13.6	12.9	13.9	13.9	14.0	14.1	14.9	15.5	15.0	14.6	15.0	15.3	16.2	17.0	17.5						
8-year	13.1	12.8	11.9	13.0	13.1	13.0	12.8	13.9	14.7	13.6	13.7	14.0	13.6	15.2	15.8							
9-year	12.4	11.9	11.2	12.1	12.3	11.9	11.9	13.1	13.8	12.8	12.6	13.1	12.6	14.2								
10-year	11.6	11.1	10.4	11.3	11.6	11.0	11.2	12.4	13.1	12.0	12.1	12.3	11.8									
11-year	11.1	10.5	9.8	10.6	10.9	10.6	10.6	11.9	12.1	11.3	11.3	11.2										
12-year	10.6	9.9	9.2	9.9	10.1	10.0	9.9	11.3	11.4	10.6	10.5											
13-year	10.2	9.3	8.8	9.4	9.4	9.5	9.4	10.4	10.6	10.2												
14-year	9.6	8.9	8.2	8.9	8.7	9.0	8.9	9.7	9.9													
15-year	9.1	8.4	7.8	8.4	8.4	8.6	8.3	9.1														
16-year	8.8	8.0	7.4	7.9	7.8	8.1	7.5															
17-year	8.4	7.7	7.0	7.4	7.3	7.6																
18-year	8.0	7.2	6.7	7.0	6.8																	
19-year	7.7	6.6	6.3	6.5																		
20-year	7.4	6.2	6.1																			
21-year	6.9	5.9	5.8																			
22-year	6.5	5.6	5.5																			
23-year	6.2	5.3	5.3																			
24-year	6.0	5.1	5.1																			
25-year	5.7	4.8																				
26-year	5.5	4.6																				
27-year	5.3	4.2																				
28-year	5.1	3.9																				
29-year	4.8	3.7																				
30-year	4.5																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 16.9  
 Melanoma of the Skin (Invasive)  
 SEER<sup>a</sup> Relative Survival (Percent)  
 By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	94.2	95.6	96.3	96.7	97.3	97.6	96.6	96.6	97.6	97.9	97.4	97.8	97.7	97.7	97.9	97.6	97.8	97.9	98.1	97.7	97.6	97.9
2-year	89.8	91.6	93.2	93.8	94.2	95.7	94.3	94.4	95.5	96.1	95.5	95.5	96.0	96.2	96.3	96.1	96.2	95.8	95.9	96.6	96.1	
3-year	86.1	88.0	90.7	91.9	92.6	93.8	92.2	92.7	94.0	94.5	94.0	94.3	94.9	94.5	95.0	94.6	94.6	94.6	94.6	94.6	95.0	
4-year	83.4	85.5	89.1	90.2	91.2	93.1	91.2	91.4	93.2	93.2	92.7	93.2	93.6	93.5	94.2	93.7	94.0	93.9	93.5			
5-year	82.0	83.5	87.7	89.3	90.1	92.2	89.8	90.8	92.3	92.0	92.1	92.9	93.2	93.1	93.2	92.9	93.2	93.3				
6-year	80.3	82.2	86.6	88.4	90.0	91.5	89.2	90.3	91.6	91.7	91.3	92.5	92.3	93.1	92.9	92.1	92.6					
7-year	78.9	81.6	85.8	87.8	90.0	91.1	88.5	90.2	91.6	91.4	91.1	92.0	91.8	92.3	92.8	91.8						
8-year	77.9	80.9	85.2	87.1	89.7	90.8	87.8	89.8	91.1	91.4	90.9	91.1	91.6	92.2	92.6							
9-year	77.0	80.2	84.9	86.9	89.4	90.3	87.6	89.6	90.8	91.4	90.7	90.6	91.6	92.0								
10-year	76.5	79.6	84.8	86.8	89.3	89.8	87.6	89.1	90.8	91.1	90.1	90.5	91.3									
11-year	76.0	79.3	84.3	86.5	89.0	89.6	87.6	89.1	90.8	90.7	90.0	90.3										
12-year	75.5	79.1	84.1	86.3	89.0	89.5	87.0	88.6	90.8	90.7	89.9											
13-year	75.2	78.7	84.0	86.3	88.5	89.4	86.7	88.5	90.8	90.7												
14-year	75.0	78.4	83.8	86.2	88.5	89.3	86.5	88.4	90.8													
15-year	74.6	78.2	83.8	86.2	88.5	89.3	86.3	88.2														
16-year	74.4	78.2	83.7	86.1	88.5	89.2	86.3															
17-year	74.4	77.9	83.7	86.1	88.5	88.8																
18-year	74.3	77.8	83.7	86.1	88.5																	
19-year	74.3	77.8	83.7	86.1																		
20-year	74.3	77.8	83.7																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 16.10  
Melanoma of the Skin (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	92.4	94.0	95.2	96.1	96.3	96.6	96.2	96.3	97.1	97.4	96.5	96.8	97.0	97.5	97.6	97.1	97.5	97.0	97.3	97.2	97.0	97.2
2-year	86.6	88.7	91.3	92.5	92.0	94.3	93.3	93.7	94.3	95.4	93.8	94.0	94.8	95.6	95.8	95.4	95.3	94.6	94.5	95.9	95.1	
3-year	82.3	84.2	88.2	90.2	89.9	92.0	90.7	91.9	92.5	93.5	91.5	92.4	93.4	92.7	94.0	93.5	93.2	93.0	93.0	93.9		
4-year	78.9	81.2	86.1	88.3	87.9	91.1	89.8	90.4	91.3	92.0	89.8	90.8	91.8	91.8	92.7	92.6	92.6	92.1	91.8			
5-year	77.5	78.6	84.4	87.2	86.6	90.3	88.0	90.0	90.3	90.9	89.1	90.3	91.6	91.1	91.4	91.6	91.6	91.6				
6-year	75.5	77.2	83.1	86.2	86.3	89.5	87.2	89.4	89.0	90.3	88.2	89.9	90.6	91.1	90.9	90.7	90.8					
7-year	73.8	76.8	82.1	85.3	86.3	89.3	86.9	89.4	88.9	90.2	88.0	89.5	89.6	90.1	90.5	90.3						
8-year	72.6	75.9	81.5	84.6	86.0	88.9	86.1	89.1	88.6	90.0	87.9	88.4	89.3	89.7	89.9							
9-year	71.6	75.1	81.1	84.3	85.6	88.3	85.9	88.6	88.4	90.0	87.9	87.7	89.3	89.4								
10-year	71.2	74.7	81.1	84.1	85.4	87.8	85.5	88.1	88.3	89.9	87.3	87.7	89.3									
11-year	70.3	74.2	81.0	83.7	85.4	87.6	85.5	88.0	88.3	89.3	87.0	87.7										
12-year	69.9	74.1	80.8	83.7	85.4	87.6	84.6	87.3	88.3	89.1	87.0											
13-year	69.4	73.8	80.7	83.6	85.4	87.6	84.6	87.2	88.3	89.1												
14-year	69.4	73.4	80.3	83.4	85.4	87.6	84.0	87.0	88.3													
15-year	69.2	73.4	80.1	83.4	85.4	87.6	84.0	87.0														
16-year	68.9	73.4	79.8	83.4	85.1	87.6	84.0															
17-year	68.9	73.4	79.8	83.4	85.1	87.6																
18-year	68.9	73.4	79.8	83.4	85.1																	
19-year	68.9	73.4	79.8	83.4																		
20-year	68.9	73.4	79.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 16.11  
Melanoma of the Skin (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	96.1	97.3	97.6	97.4	98.5	98.8	97.1	97.0	98.2	98.4	98.5	99.0	98.6	98.0	98.3	98.1	98.1	98.9	99.1	98.3	98.4	98.9
2-year	92.9	94.7	95.3	95.4	96.7	97.3	95.4	95.2	96.9	97.0	97.6	97.2	97.5	96.8	96.8	97.0	97.2	97.3	97.8	97.2	97.4	
3-year	89.9	91.9	93.5	93.8	95.7	95.9	94.0	93.6	95.6	95.7	97.1	96.4	96.5	96.5	96.1	95.9	96.3	96.6	96.5	96.3		
4-year	87.8	89.8	92.4	92.5	94.9	95.3	92.8	92.6	95.3	94.6	96.2	95.9	95.6	95.5	95.9	95.0	95.6	96.1	95.7			
5-year	86.4	88.5	91.3	91.8	94.1	94.6	91.8	91.6	94.6	93.4	95.6	95.7	95.0	95.3	95.3	94.4	95.2	95.4				
6-year	84.9	87.3	90.3	91.1	94.1	93.8	91.5	91.1	94.4	93.3	95.1	95.3	94.3	95.3	95.0	93.8	94.7					
7-year	83.9	86.5	89.8	90.6	94.1	93.3	90.4	90.9	94.3	92.8	94.7	94.7	94.1	94.8	95.0	93.6						
8-year	83.0	85.9	89.2	90.2	94.0	93.2	89.7	90.4	93.7	92.8	94.2	94.2	93.9	94.8	95.0							
9-year	82.3	85.4	89.0	90.0	93.6	92.8	89.5	90.4	93.6	92.8	93.7	93.9	93.8	94.6								
10-year	81.7	84.7	88.8	89.9	93.6	92.3	89.5	90.1	93.5	92.6	93.3	93.3	93.6									
11-year	81.4	84.4	88.0	89.7	92.8	91.9	89.5	90.1	93.5	92.5	93.3	93.1										
12-year	80.9	84.1	87.8	89.5	92.8	91.4	89.5	90.1	93.5	92.4	93.2											
13-year	80.7	83.6	87.5	89.5	91.8	91.3	89.0	89.9	93.5	92.4												
14-year	80.2	83.5	87.4	89.4	91.6	91.2	89.0	89.9	93.5													
15-year	79.8	82.9	87.4	89.4	91.6	90.4	88.7	89.5														
16-year	79.6	82.7	87.4	89.3	91.6	89.9	88.6															
17-year	79.6	82.4	87.4	89.3	91.6	89.5																
18-year	79.6	82.2	87.4	89.3	91.6																	
19-year	79.5	82.2	87.4	89.3																		
20-year	79.5	82.2	87.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 17.5  
MesotheliomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	34.8	37.7	35.7	35.9	35.8	41.9	35.3	37.4	31.7	40.5	40.4	31.7	46.6	39.5	40.6	44.5	42.3	45.0	45.4	33.5	47.3	40.1
2-year	15.9	18.7	16.5	15.7	13.8	25.1	16.9	21.2	18.6	14.6	24.0	15.6	22.3	16.6	19.7	28.4	18.7	20.7	26.1	16.5	26.1	
3-year	10.8	11.7	10.8	10.9	11.8	17.5	10.3	14.7	12.8	10.5	13.8	6.9	16.8	10.4	12.7	19.6	11.5	14.5	16.3	8.5		
4-year	9.2	8.4	8.0	8.2	8.9	11.4	7.8	12.6	10.5	7.0	11.4	4.7	13.5	8.5	10.3	14.8	7.1	11.9	14.3			
5-year	7.9	7.0	6.6	7.1	7.1	10.2	5.7	12.6	8.2	3.1	10.9	4.2	9.0	6.0	9.3	12.6	4.8	9.8				
6-year	6.7	5.7	5.2	6.0	6.1	10.0	4.6	11.3	7.8	1.3	9.9	3.7	8.0	6.0	9.3	11.3	4.2					
7-year	6.0	5.1	4.5	5.6	5.1	8.6	3.0	10.6	7.4	1.3	7.7	3.2	6.9	4.4	9.1	10.3						
8-year	5.6	4.8	4.0	5.0	5.1	6.5	3.0	8.5	7.4	0.7	7.7	3.2	5.7	3.8	8.3							
9-year	5.3	4.6	3.8	4.7	3.0	4.9	2.5	8.5	6.0	0.7	7.7	3.2	5.7	3.2								
10-year	5.2	4.3	3.4	4.3	3.0	4.4	2.5	7.7	6.0	0.7	6.8	3.0	4.0									
11-year	5.0	4.3	3.4	4.1	3.0	4.0	1.9	7.4	5.6	0.7	5.0	3.0										
12-year	4.9	4.1	3.4	3.8	2.5	3.5	1.9	5.6	5.6	0.7	5.0											
13-year	4.7	4.0	3.3	3.6	2.5	3.0	1.9	5.6	5.6	0.7												
14-year	4.7	4.0	3.3	3.6	2.5	3.0	1.9	5.6	5.1													
15-year	4.3	3.5	3.2	3.6	2.5	3.0	1.9	5.6														
16-year	4.1	3.5	3.2	3.6	2.5	3.0	1.9															
17-year	4.0	3.5	3.2	3.6	2.5	2.9																
18-year	4.0	3.5	3.2	3.2	2.5																	
19-year	4.0	3.5	3.2	2.4																		
20-year	4.0	3.5	3.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 17.6  
MesotheliomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	32.9	36.0	33.8	32.8	34.9	45.0	32.7	32.8	28.8	41.3	36.5	30.6	44.9	37.5	40.5	39.9	40.7	41.8	46.2	30.9	45.8	40.0
2-year	11.1	15.9	14.2	11.7	11.1	24.5	14.3	17.6	13.7	13.5	20.3	14.5	18.5	14.7	17.3	22.0	15.2	19.3	25.6	16.0	22.4	
3-year	6.6	9.5	8.4	7.4	8.9	16.2	8.7	11.7	6.8	9.0	10.8	6.0	13.9	8.9	8.9	12.8	10.5	13.6	13.9	6.2		
4-year	5.2	6.6	5.8	4.7	5.9	11.3	6.2	10.1	4.4	6.7	8.8	3.1	12.6	6.6	6.3	9.4	5.9	11.2	11.0			
5-year	4.0	5.1	4.6	3.6	4.2	10.3	3.6	10.1	3.8	4.0	8.2	3.1	7.1	3.9	6.3	7.6	4.3	8.5				
6-year	3.3	4.3	3.2	3.1	3.5	10.3	2.2	8.2	3.8	1.7	7.5	2.4	6.5	3.9	6.3	6.3	4.3					
7-year	2.6	3.4	2.5	2.6	2.2	9.5	1.5	7.8	3.8	1.7	5.1	1.6	5.7	2.1	6.3	6.3						
8-year	2.3	3.3	2.5	2.1	2.2	6.7	1.5	4.8	3.8	0.9	5.1	1.6	5.7	2.1	6.2							
9-year	2.1	3.1	2.2	1.8	0.0	5.2	0.8	4.8	2.8	0.9	5.1	1.6	5.7	1.1								
10-year	2.1	3.1	1.9	1.7	0.0	4.5	0.8	4.1	2.8	0.9	5.1	1.6	4.5									
11-year	2.1	3.1	1.9	1.6	0.0	3.9	0.0	4.1	2.2	0.9	2.8	1.6										
12-year	1.9	2.9	1.9	1.4	0.0	3.2	0.0	3.6	2.2	0.9	2.8											
13-year	1.7	2.8	1.8	1.4	0.0	2.3	0.0	3.6	2.2	0.9												
14-year	1.4	2.8	1.7	1.4	0.0	2.3	0.0	3.6	1.6													
15-year	1.1	2.5	1.6	1.4	0.0	2.3	0.0	3.6														
16-year	1.1	2.5	1.6	1.4	0.0	2.3	0.0															
17-year	1.1	2.4	1.6	1.2	0.0	1.8																
18-year	1.1	2.4	1.6	1.2	0.0																	
19-year	1.1	2.4	1.6	0.7																		
20-year	1.1	2.4	1.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 17.7  
MesotheliomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	40.8	43.7	42.3	48.0	38.8	32.3	46.3	54.5	43.7	37.1	52.3	35.7	51.2	46.0	41.0	57.0	46.7	57.8	42.9	42.5	52.3	40.6
2-year	31.1	28.3	24.5	31.2	23.1	26.8	27.9	34.8	39.3	19.0	34.8	19.4	32.9	22.3	27.9	45.8	27.9	26.1	27.2	18.4	38.4	
3-year	24.4	19.4	18.9	24.4	21.2	21.3	17.2	26.0	37.4	16.7	22.8	9.8	24.8	14.3	25.9	37.8	14.3	17.8	23.0	16.5		
4-year	21.5	14.4	15.4	21.3	19.3	11.8	14.4	21.6	35.4	8.6	18.8	9.8	16.0	14.3	23.7	29.3	10.3	15.2	23.0			
5-year	20.1	13.3	13.4	20.2	17.6	9.8	14.4	21.6	26.2	0.0	18.8	7.8	14.2	12.4	19.3	26.0	6.3	15.2				
6-year	17.1	10.5	11.9	16.9	15.2	7.9	14.4	21.6	23.8	0.0	16.9	7.8	12.2	12.4	19.3	24.9	4.3					
7-year	16.3	10.5	10.8	16.5	15.2	6.0	8.9	20.5	21.4	0.0	15.0	7.8	10.2	10.4	17.6	21.1						
8-year	15.7	9.9	8.7	15.8	15.2	6.0	8.9	20.5	21.4	0.0	15.0	7.8	5.2	8.4	15.5							
9-year	15.2	9.5	8.7	15.3	12.9	4.0	8.9	20.5	19.0	0.0	15.0	7.8	5.2	8.4								
10-year	14.4	7.7	8.4	14.0	12.9	4.0	8.9	20.1	19.0	0.0	11.1	6.8	2.9									
11-year	13.7	7.7	8.4	13.7	12.9	4.0	8.9	18.1	19.0	0.0	11.1	6.8										
12-year	13.7	7.7	8.1	12.7	10.5	4.0	8.9	12.6	19.0	0.0	11.1											
13-year	13.7	7.7	8.1	11.8	10.5	4.0	8.9	12.6	19.0	0.0												
14-year	13.7	7.7	8.1	11.8	10.5	4.0	8.9	12.6	19.0													
15-year	13.7	6.8	8.1	11.6	10.5	4.0	8.9	12.6														
16-year	12.9	6.8	8.1	11.6	10.5	4.0	8.9															
17-year	12.3	6.8	8.1	11.6	10.5	4.0																
18-year	12.3	6.8	7.9	10.5	10.5																	
19-year	12.3	6.8	7.9	8.7																		
20-year	12.3	6.5	7.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 18.9  
MyelomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	68.0	69.5	72.3	71.9	73.9	70.6	74.3	74.9	73.6	72.4	72.6	73.5	77.2	74.6	76.0	74.0	76.9	77.6	81.8	81.3	79.4	80.9
2-year	52.1	54.5	57.6	57.4	58.8	57.6	60.6	62.3	59.8	59.9	59.6	62.7	64.9	66.2	64.6	66.1	66.4	68.6	72.4	71.8	71.0	
3-year	39.6	42.8	45.3	46.2	47.9	44.9	48.7	51.1	47.9	50.0	49.4	53.3	55.7	58.4	57.2	57.9	57.6	61.3	64.8	65.0		
4-year	31.5	34.2	35.7	36.9	40.1	38.2	38.7	39.8	38.8	41.3	43.9	46.6	47.6	50.4	50.4	50.9	49.9	55.3	58.9			
5-year	25.1	26.9	27.5	29.9	33.4	31.8	31.3	34.2	31.3	34.5	37.3	39.7	41.9	44.9	46.1	45.8	45.6	49.6				
6-year	20.1	21.0	22.1	24.5	28.3	27.1	26.3	29.7	27.2	29.2	32.5	35.0	37.5	39.5	41.1	40.6	40.5					
7-year	16.2	16.7	17.5	20.4	23.7	23.7	22.5	24.4	23.5	25.4	29.0	31.4	32.9	35.1	36.2	35.8						
8-year	13.5	13.4	14.9	17.3	20.4	21.4	19.8	22.2	20.2	22.7	25.5	28.2	29.7	31.3	33.1							
9-year	11.5	11.2	11.9	15.3	18.3	19.5	17.1	19.5	18.4	20.5	22.9	25.3	26.7	29.4								
10-year	9.8	9.6	10.4	13.7	17.2	17.2	15.5	17.8	16.4	19.4	20.9	22.5	23.7									
11-year	8.7	8.6	9.2	12.6	15.6	15.6	14.3	16.7	14.2	18.4	19.5	19.5										
12-year	7.8	7.6	8.4	11.1	14.3	14.8	12.9	14.9	13.7	17.0	18.5											
13-year	6.7	6.6	7.6	10.2	13.5	13.3	11.7	14.0	12.7	15.9												
14-year	6.1	6.0	7.0	9.5	12.4	12.6	11.0	13.7	11.4													
15-year	5.3	5.7	6.1	9.2	11.9	11.4	10.8	12.1														
16-year	4.9	5.1	5.7	8.6	10.8	9.7	10.3															
17-year	4.6	4.7	5.4	8.1	10.0	8.8																
18-year	4.0	4.3	5.0	7.5	9.8																	
19-year	3.8	3.8	4.9	6.8																		
20-year	3.3	3.5	4.7																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 18.10  
MyelomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	67.8	69.6	73.2	72.5	74.2	71.2	74.1	76.2	75.6	73.6	74.2	74.2	76.9	76.6	76.1	73.7	77.5	76.6	83.6	83.0	79.8	79.8
2-year	52.3	54.7	59.3	58.4	59.8	58.3	61.0	63.6	61.3	61.6	61.5	61.4	65.3	67.9	64.0	66.7	68.0	67.5	73.6	73.5	71.8	
3-year	39.0	42.8	46.2	46.6	49.2	45.0	50.3	53.4	50.7	52.5	50.8	52.4	56.3	60.1	56.4	58.1	59.9	58.8	66.1	66.0		
4-year	30.8	33.6	36.6	37.0	41.2	39.8	40.8	43.6	42.7	43.2	45.8	46.6	47.7	51.3	50.2	51.6	51.7	52.2	60.5			
5-year	24.3	25.8	28.4	30.3	36.2	33.7	31.5	38.0	34.6	35.8	39.7	41.4	42.2	45.8	46.7	47.3	47.5	47.0				
6-year	19.2	20.8	23.5	25.2	31.6	29.7	26.4	33.9	29.8	30.0	34.8	36.1	37.7	39.9	41.0	42.8	42.4					
7-year	15.4	16.9	19.1	21.3	26.0	25.8	22.3	28.0	25.9	26.0	31.0	32.7	34.2	35.6	35.5	37.3						
8-year	13.0	13.8	16.2	18.6	22.0	23.9	20.1	25.5	21.5	23.3	27.0	29.4	30.6	32.2	33.4							
9-year	11.0	11.7	12.9	16.7	20.0	21.2	18.1	23.3	19.3	19.7	24.3	26.3	28.2	30.3								
10-year	9.2	9.9	11.2	14.8	19.0	18.3	16.3	21.6	17.3	18.4	21.6	23.6	23.5									
11-year	7.5	8.9	9.9	13.6	17.3	17.0	14.8	20.7	14.2	17.0	20.4	20.9										
12-year	6.9	7.7	9.4	12.0	15.4	16.6	14.3	18.6	13.5	15.5	19.2											
13-year	5.8	6.7	8.6	11.2	14.8	14.4	13.0	17.1	12.7	14.6												
14-year	5.2	6.1	8.0	10.4	13.1	14.0	12.6	16.7	11.1													
15-year	4.6	5.7	7.0	10.0	12.9	12.6	12.1	15.8														
16-year	4.4	5.2	6.7	9.6	11.1	9.5	11.6															
17-year	3.9	4.8	6.3	8.9	10.3	9.2																
18-year	3.5	4.4	6.1	8.1	9.9																	
19-year	3.3	4.2	6.1	7.2																		
20-year	2.6	3.9	5.9																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 18.11  
MyelomaSEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	68.2	69.3	71.2	71.1	73.6	69.9	74.6	73.4	71.3	71.0	70.8	72.6	77.5	72.2	75.9	74.4	76.2	78.7	79.7	79.0	78.9	82.4
2-year	52.0	54.3	55.9	56.3	57.8	56.8	60.1	60.9	58.1	57.9	57.6	64.4	64.4	64.2	65.3	65.5	64.2	69.8	70.9	69.7	69.9	
3-year	40.4	42.9	44.3	45.7	46.3	44.9	46.9	48.5	44.8	47.1	47.7	54.5	54.9	56.3	58.0	57.7	54.3	63.9	63.2	63.8		
4-year	32.2	34.8	34.7	36.8	39.0	36.4	36.5	35.6	34.4	39.0	41.7	46.7	47.5	49.4	50.5	50.0	47.5	58.6	57.1			
5-year	26.1	28.0	26.5	29.4	30.2	29.8	31.1	29.9	27.7	32.9	34.6	37.5	41.5	44.0	45.4	44.3	42.9	52.4				
6-year	21.0	21.2	20.7	23.7	24.7	24.4	26.3	25.2	24.2	28.3	29.9	33.6	37.2	38.9	41.2	38.2	37.8					
7-year	17.1	16.4	15.9	19.4	21.3	21.5	22.6	20.4	20.7	24.5	26.7	29.7	31.4	34.5	37.0	34.3						
8-year	14.1	13.0	13.7	15.9	18.5	18.6	19.4	18.5	18.6	21.9	23.7	26.7	28.6	30.1	32.6							
9-year	12.0	10.7	10.9	13.9	16.3	17.7	16.1	15.4	17.2	21.5	21.3	24.0	25.1	28.3								
10-year	10.5	9.4	9.6	12.4	15.1	15.9	14.5	13.8	15.4	20.5	20.0	21.2	23.9									
11-year	10.0	8.4	8.4	11.6	13.7	14.1	13.6	12.3	14.1	20.0	18.5	17.6										
12-year	8.7	7.5	7.3	10.1	12.8	13.0	11.4	10.9	13.9	18.5	17.7											
13-year	7.5	6.5	6.7	9.2	12.0	11.9	10.2	10.6	12.6	17.5												
14-year	6.9	6.0	6.0	8.5	11.4	11.0	9.4	10.4	11.7													
15-year	6.0	5.6	5.2	8.2	10.8	10.2	9.4	8.0														
16-year	5.4	5.0	4.7	7.5	10.3	9.8	8.9															
17-year	5.2	4.5	4.5	7.2	9.5	8.3																
18-year	4.5	4.1	4.0	6.7	9.5																	
19-year	4.3	3.4	3.8	6.4																		
20-year	3.9	3.1	3.5																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.9  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	70.2	73.0	71.3	70.4	70.2	73.2	75.6	76.7	77.4	77.3	78.7	81.0	80.3	81.1	81.6	81.0	81.6	84.0	83.9	84.2	83.3	84.0
2-year	60.2	63.7	62.8	62.2	61.7	65.8	68.5	70.0	71.0	71.4	73.3	76.0	75.6	76.0	77.2	76.9	77.4	78.9	79.4	79.4	79.5	
3-year	54.6	58.5	58.2	57.7	57.4	62.0	64.8	66.3	66.9	67.8	70.0	73.1	73.0	73.5	74.7	74.5	74.9	76.0	77.1	77.2		
4-year	50.5	54.6	54.3	54.4	54.6	58.6	62.1	63.5	64.4	65.4	68.0	71.1	71.5	71.4	72.8	72.6	73.0	74.2	75.3			
5-year	46.8	50.7	51.0	51.6	51.9	56.0	59.4	60.9	62.0	63.8	65.9	69.2	69.9	70.1	71.4	70.5	71.1	72.5				
6-year	43.6	47.5	48.3	49.2	49.8	54.1	57.1	58.3	59.4	62.0	64.6	68.0	68.2	68.7	70.2	68.8	70.0					
7-year	40.8	45.0	45.8	46.9	47.8	52.1	55.1	56.4	57.7	60.4	62.8	66.2	67.0	67.1	68.2	67.2						
8-year	38.5	42.8	43.4	45.0	46.3	50.4	52.8	55.1	56.2	58.8	61.2	65.0	65.6	66.5	66.7							
9-year	36.6	40.8	41.4	43.4	45.1	49.3	51.4	53.4	54.7	57.4	59.8	63.9	64.6	64.7								
10-year	35.0	38.9	39.8	42.0	44.2	48.0	50.0	52.1	53.5	56.2	58.8	63.1	63.1									
11-year	33.5	37.4	38.4	40.5	43.2	46.6	48.6	50.9	52.5	54.6	57.9	61.7										
12-year	32.3	35.9	36.9	39.5	42.1	45.6	48.0	50.0	51.1	53.3	56.6											
13-year	31.4	34.7	35.7	38.3	41.3	44.8	46.7	49.0	49.9	51.8												
14-year	30.2	33.5	34.7	37.1	40.4	44.2	45.4	48.3	48.7													
15-year	28.8	32.2	33.5	36.4	39.6	43.6	44.4	47.2														
16-year	27.9	31.1	32.7	35.5	39.0	43.5	43.0															
17-year	27.3	30.3	32.1	34.7	38.5	42.7																
18-year	26.7	29.5	31.3	33.9	37.5																	
19-year	26.0	28.7	30.5	33.1																		
20-year	25.1	27.9	30.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 19.10  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	69.4	72.7	68.9	67.1	66.6	71.2	74.7	74.9	75.8	76.5	77.6	80.6	79.6	80.1	81.0	81.0	81.4	83.5	82.7	83.6	83.6	83.8
2-year	59.4	63.7	60.5	58.2	58.3	63.6	67.1	68.2	69.1	70.3	71.2	75.2	74.8	75.4	76.1	76.5	77.8	77.7	78.0	78.6	79.5	
3-year	53.4	58.0	55.7	53.7	54.5	59.8	63.8	64.5	64.4	66.7	67.9	72.0	72.5	72.6	73.0	73.6	75.3	75.0	75.5	76.3		
4-year	49.3	53.9	51.6	50.4	51.5	56.1	61.0	61.9	61.5	63.9	65.6	70.0	70.8	70.0	70.9	71.4	73.3	73.1	73.4			
5-year	45.4	50.1	48.2	47.6	48.5	53.6	58.2	59.1	59.0	61.7	63.5	67.9	68.8	68.7	69.7	68.9	70.9	71.9				
6-year	42.6	46.6	45.5	45.5	46.8	51.0	56.1	56.4	56.2	60.2	61.9	66.7	66.8	67.4	68.2	67.0	69.5					
7-year	39.9	44.2	43.1	43.6	44.8	49.1	54.2	54.4	54.6	58.6	60.0	65.2	65.6	65.3	66.6	65.1						
8-year	37.8	42.0	40.9	41.7	43.2	47.4	52.0	53.2	53.5	56.6	58.1	63.7	64.3	64.7	64.7							
9-year	35.7	40.1	39.1	40.1	42.2	46.4	50.4	51.3	52.3	55.2	57.1	62.8	63.1	62.9								
10-year	34.0	38.0	37.7	39.1	41.5	45.4	48.8	50.2	51.5	54.1	55.9	61.7	61.5									
11-year	32.8	36.3	36.4	38.0	40.7	43.7	47.5	49.2	50.7	52.6	54.5	60.2										
12-year	31.9	35.2	35.1	37.1	39.4	42.6	47.0	48.0	49.8	51.3	53.5											
13-year	30.7	34.2	34.2	36.1	38.8	41.9	45.4	46.5	49.0	50.0												
14-year	29.4	33.0	33.2	34.9	37.6	41.3	44.2	45.9	47.9													
15-year	28.0	31.9	32.3	34.3	36.7	40.8	43.3	45.1														
16-year	27.1	30.7	31.5	33.2	35.9	40.8	42.3															
17-year	26.5	29.9	30.8	32.5	35.6	40.3																
18-year	26.0	29.3	30.2	31.8	34.8																	
19-year	25.5	28.7	29.3	31.1																		
20-year	24.9	27.9	29.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 19.11  
Non-Hodgkin Lymphoma

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	71.0	73.4	74.0	74.7	75.1	75.8	76.7	78.6	79.2	78.2	80.0	81.4	81.0	82.2	82.4	80.9	81.9	84.6	85.3	85.0	82.8	84.1
2-year	61.1	63.7	65.6	67.2	66.3	68.7	70.1	72.0	73.3	72.7	75.7	76.8	76.5	76.7	78.4	77.3	77.1	80.3	81.1	80.6	79.4	
3-year	55.9	58.9	61.1	62.8	61.4	64.9	66.1	68.4	69.9	69.2	72.6	74.3	73.6	74.6	76.7	75.5	74.5	77.3	79.0	78.3		
4-year	51.9	55.2	57.6	59.5	58.8	61.8	63.4	65.3	68.0	67.4	70.9	72.4	72.3	73.0	75.0	73.9	72.8	75.4	77.6			
5-year	48.2	51.3	54.3	56.7	56.3	59.0	60.7	62.9	65.6	66.4	68.8	70.7	71.2	71.6	73.4	72.4	71.3	73.3				
6-year	44.6	48.4	51.7	53.9	53.8	57.9	58.3	60.3	63.3	64.3	67.8	69.4	69.9	70.2	72.4	70.8	70.5					
7-year	41.7	45.8	49.0	51.1	51.7	55.9	56.2	58.5	61.3	62.5	66.2	67.2	68.6	69.2	70.1	69.6						
8-year	39.2	43.7	46.3	49.1	50.3	54.1	53.9	57.3	59.4	61.4	64.8	66.6	67.1	68.4	69.0							
9-year	37.5	41.6	44.3	47.5	48.9	52.8	52.7	55.7	57.6	60.2	63.1	65.2	66.3	66.8								
10-year	36.0	39.8	42.4	45.8	47.7	51.3	51.5	54.1	56.0	58.6	62.3	64.6	64.9									
11-year	34.2	38.5	40.9	43.8	46.6	50.2	49.9	52.7	54.5	57.0	61.9	63.3										
12-year	32.9	36.8	39.0	42.4	45.7	49.3	49.2	52.2	52.7	55.7	60.3											
13-year	32.1	35.2	37.5	41.0	44.6	48.4	48.3	51.6	50.8	53.9												
14-year	31.0	34.0	36.5	39.9	43.9	47.7	46.8	51.0	49.4													
15-year	29.7	32.5	34.9	39.0	43.3	47.0	45.7	49.5														
16-year	28.7	31.5	34.2	38.4	43.1	46.4	43.7															
17-year	28.2	30.6	33.6	37.6	42.4	45.6																
18-year	27.4	29.8	32.7	36.6	40.8																	
19-year	26.5	28.7	32.0	35.6																		
20-year	25.4	28.0	31.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 20.12  
Cancer of the Oral Cavity and Pharynx (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	79.3	79.1	80.4	81.1	82.7	81.8	83.3	80.7	83.6	84.5	82.4	83.4	83.9	84.4	83.4	85.0	84.8	86.2	85.9	87.2	87.0	85.6
2-year	65.8	65.9	67.5	69.4	71.5	69.7	71.2	70.0	72.3	73.6	73.0	72.7	75.0	75.3	73.9	75.2	76.0	77.4	77.5	78.4	78.4	
3-year	59.8	59.5	61.0	63.1	65.2	63.5	66.1	64.2	65.5	68.7	67.0	67.4	70.3	70.7	68.6	70.5	71.2	71.7	73.0	74.0		
4-year	55.9	55.5	57.1	59.0	61.3	60.0	62.1	60.0	62.1	64.8	62.4	64.1	67.0	66.8	65.8	67.2	68.2	68.2	69.6			
5-year	52.8	52.3	53.9	56.1	58.5	57.7	58.5	57.0	58.9	62.0	60.0	61.7	65.1	64.8	63.9	64.9	66.3	66.2				
6-year	50.5	49.6	51.5	53.6	55.9	55.2	56.0	55.4	56.2	59.8	57.9	59.9	63.8	62.1	61.6	62.6	64.8					
7-year	48.4	47.4	49.0	51.5	53.4	53.3	54.2	53.8	53.9	57.8	56.1	58.4	62.3	60.4	59.8	61.1						
8-year	46.2	45.9	46.9	49.4	51.2	51.0	53.1	52.6	52.1	55.5	53.8	56.1	60.7	59.1	58.0							
9-year	44.3	43.9	45.0	47.1	49.3	49.7	51.6	52.0	50.3	53.8	51.5	54.4	58.2	57.0								
10-year	42.3	42.2	43.3	45.4	47.7	47.6	49.9	50.9	48.9	52.1	49.3	52.4	57.3									
11-year	40.4	40.7	42.0	43.6	45.9	46.2	47.8	48.7	48.0	50.4	48.1	50.7										
12-year	39.0	39.3	40.5	42.4	44.0	45.3	46.0	47.5	46.6	48.6	46.3											
13-year	37.7	37.5	38.9	40.8	42.3	43.0	44.6	45.9	46.0	47.6												
14-year	36.7	36.5	37.6	39.6	39.9	41.2	43.7	44.0	44.6													
15-year	35.3	34.9	36.6	38.5	38.3	39.9	42.3	43.3														
16-year	33.9	33.7	35.5	37.4	37.4	38.9	41.1															
17-year	32.9	32.8	34.5	36.3	36.3	38.0																
18-year	31.9	31.7	33.1	35.1	34.9																	
19-year	31.0	30.1	31.9	34.1																		
20-year	29.9	29.5	31.3																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 20.13  
Cancer of the Oral Cavity and Pharynx For Selected Subsites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
<u>Cancer of the Tongue</u>																						
1-year	74.2	73.3	76.8	79.5	79.3	79.1	81.4	79.9	80.5	84.6	80.8	81.0	84.3	86.7	84.8	84.2	85.9	86.7	87.5	86.5	87.9	87.5
2-year	54.9	57.5	60.5	64.8	65.2	66.6	71.0	65.8	68.2	71.5	70.6	69.3	71.3	75.6	72.2	73.7	76.3	76.8	79.0	76.3	78.3	
3-year	47.4	50.8	54.3	57.4	58.6	60.4	65.0	59.1	60.0	66.0	63.8	63.8	66.8	70.9	65.1	69.1	70.4	71.9	73.7	71.5		
4-year	43.5	47.4	49.8	53.6	56.4	57.3	61.9	55.5	57.9	63.3	61.0	61.5	64.1	66.6	61.6	66.7	68.7	69.5	71.0			
5-year	40.1	44.6	47.3	50.8	54.0	55.4	57.9	52.8	54.7	62.0	58.4	59.6	61.3	64.9	60.2	64.9	66.7	67.3				
6-year	38.4	41.8	45.1	48.5	50.4	52.8	56.3	52.2	52.8	60.1	56.3	57.5	60.9	61.6	59.2	63.3	65.4					
7-year	37.2	38.9	42.3	46.7	48.4	51.2	55.0	49.4	50.5	57.8	54.3	56.5	59.3	59.2	57.8	62.6						
8-year	35.7	37.4	40.3	44.3	46.5	49.8	53.8	47.8	50.4	55.7	50.6	53.2	58.8	56.8	56.1							
9-year	34.2	34.8	38.8	42.0	44.6	48.6	52.8	47.2	48.5	54.7	48.1	51.9	56.8	54.9								
10-year	32.5	33.3	37.4	40.0	43.3	46.5	52.3	45.4	47.7	53.1	46.1	49.5	55.9									
<u>Cancer of the Lip</u>																						
1-year	99.1	97.6	99.2	100.0	99.9	98.1	100.0	99.2	97.3	98.1	95.1	99.3	99.3	99.6	98.2	96.8	96.1	99.8	93.6	100.0	98.3	95.4
2-year	97.4	95.8	98.0	98.8	99.4	94.1	97.0	97.9	95.1	96.2	93.7	99.3	99.2	99.6	95.3	94.4	95.5	98.2	91.9	99.5	98.3	
3-year	96.9	93.4	97.2	98.4	98.7	92.8	95.8	95.1	93.7	95.1	93.7	97.1	98.2	98.7	95.1	93.1	95.5	97.4	91.4	94.6		
4-year	95.6	92.0	96.9	97.3	96.3	91.3	93.4	93.2	92.1	92.7	90.3	97.1	98.2	95.6	95.1	89.9	94.6	93.2	90.0			
5-year	94.1	90.0	95.8	96.0	95.0	88.6	91.2	91.1	90.5	90.3	90.3	93.9	98.2	94.0	95.1	88.4	94.6	93.2				
6-year	92.3	87.6	95.0	94.6	95.0	87.4	89.4	89.4	89.3	90.3	87.6	93.6	98.2	94.0	95.1	85.5	94.6					
7-year	91.2	86.5	93.4	93.4	95.0	86.6	88.2	89.2	88.8	90.2	84.5	93.6	97.3	93.2	94.9	85.5						
8-year	89.8	86.0	91.8	92.2	90.4	83.2	88.2	86.9	88.5	90.2	82.2	93.3	97.3	93.0	91.4							
9-year	87.5	85.1	91.3	90.0	86.0	82.5	88.0	86.3	88.1	88.5	78.7	90.7	95.8	93.0								
10-year	85.8	83.4	91.3	88.2	81.9	82.5	85.5	86.3	88.1	88.3	75.9	87.7	95.3									
<u>Cancer of the Oropharynx and Tonsil</u>																						
1-year	70.5	70.6	72.9	74.4	80.3	79.7	81.1	81.1	86.9	82.2	83.7	85.2	82.6	83.9	84.1	85.2	86.2	86.1	88.6	90.3	90.7	86.4
2-year	53.3	52.8	55.9	61.3	69.6	66.3	66.8	66.9	74.8	67.1	72.0	76.0	75.3	74.9	74.4	75.1	77.5	78.5	81.1	83.4	83.7	
3-year	44.5	44.4	45.7	53.7	62.6	60.6	61.8	59.7	66.9	62.2	66.7	71.5	71.3	71.2	70.5	70.3	72.2	73.1	76.5	79.8		
4-year	38.9	39.3	41.5	49.0	58.3	54.1	56.3	54.7	63.0	57.2	60.6	67.4	68.0	67.1	66.7	68.4	70.3	69.7	73.9			
5-year	35.4	35.3	37.8	44.8	53.7	52.6	51.3	52.7	59.7	53.4	58.7	64.5	65.1	64.5	65.2	65.6	67.9	67.2				
6-year	32.1	31.8	34.6	42.5	49.9	47.7	48.3	50.8	57.5	52.0	54.7	63.6	63.5	62.4	63.9	64.9	65.9					
7-year	30.2	29.6	32.0	41.2	46.4	43.7	47.3	49.6	55.7	48.6	52.8	62.8	62.5	61.5	61.3	62.8						
8-year	26.2	28.0	30.2	39.0	45.2	42.3	46.1	48.8	52.1	46.3	52.8	59.6	60.8	60.7	59.1							
9-year	23.8	25.8	28.4	36.5	43.9	41.3	44.3	48.5	51.9	44.6	49.6	59.0	60.4	57.5								
10-year	22.5	23.2	26.2	35.3	42.7	40.1	43.6	46.3	49.8	42.7	48.5	57.1	57.9									

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 20.14  
Cancer of the Oral Cavity and Pharynx (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	78.7	78.5	79.5	80.5	82.6	81.5	82.5	80.3	83.9	84.3	82.8	83.5	84.1	85.0	83.9	84.9	85.9	86.6	86.3	87.2	87.9	86.8
2-year	65.0	65.0	66.1	68.2	70.6	69.0	69.8	70.0	71.2	73.0	73.2	71.6	74.8	75.1	74.1	74.5	76.7	78.0	77.8	77.9	78.1	
3-year	59.0	58.2	59.0	61.3	64.7	62.6	64.6	63.7	64.1	67.4	67.3	65.5	69.9	69.9	68.4	69.2	71.0	72.3	72.2	73.3		
4-year	54.7	54.0	54.8	57.0	60.3	58.8	60.0	59.1	60.5	63.7	62.1	62.3	66.6	65.5	65.5	66.0	67.5	68.4	68.2			
5-year	51.6	50.6	51.4	54.1	57.5	56.3	56.3	56.0	57.2	60.7	59.5	60.4	65.1	63.7	63.7	64.1	65.7	66.1				
6-year	49.4	48.0	49.2	51.7	54.8	53.4	53.8	54.3	54.6	58.2	57.1	58.5	64.0	61.2	60.9	62.0	64.0					
7-year	47.2	45.9	47.0	49.4	51.8	51.0	52.5	52.6	52.6	56.0	55.2	57.5	62.7	59.9	59.1	60.7						
8-year	45.2	44.3	44.6	47.6	49.4	49.1	51.4	51.1	51.1	53.6	52.6	55.3	60.9	58.1	56.9							
9-year	43.2	42.5	42.8	45.3	47.5	48.0	49.7	50.2	49.4	51.7	50.5	53.2	58.3	55.8								
10-year	41.2	40.6	40.8	43.8	45.7	45.8	48.3	49.3	48.4	49.9	48.7	51.0	57.1									
11-year	39.2	39.0	39.6	42.2	43.7	44.1	46.4	47.0	47.4	48.2	47.3	49.6										
12-year	37.9	37.8	38.2	40.8	42.0	43.2	44.5	46.1	46.3	46.2	45.8											
13-year	36.8	36.3	36.7	39.3	40.2	40.9	42.8	44.6	45.6	45.5												
14-year	35.8	35.2	35.5	38.0	36.9	39.8	41.4	42.8	43.9													
15-year	34.5	33.9	34.5	36.9	34.9	38.1	40.1	42.1														
16-year	33.1	32.7	33.6	35.7	33.9	37.1	38.7															
17-year	32.0	31.7	32.6	34.6	32.8	36.5																
18-year	31.1	30.5	31.3	33.4	31.4																	
19-year	30.4	28.7	29.8	32.6																		
20-year	29.3	28.1	29.1																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 20.15  
Cancer of the Oral Cavity and Pharynx (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	80.8	80.3	82.3	82.3	82.9	82.3	85.0	81.6	82.8	85.0	81.7	83.0	83.3	83.1	82.3	85.3	82.2	85.2	84.9	87.0	84.8	82.6
2-year	67.8	67.7	70.5	72.0	73.3	71.2	74.4	70.0	74.4	74.9	72.6	75.2	75.4	75.8	73.4	76.8	74.5	75.9	76.9	79.4	79.2	
3-year	61.5	62.4	65.3	67.0	66.3	65.4	69.4	65.3	68.5	71.5	66.4	71.5	71.0	72.5	69.2	73.6	71.5	70.2	75.2	75.7		
4-year	58.5	58.6	61.8	63.1	63.3	62.5	66.8	62.1	65.6	67.2	63.1	67.8	68.2	69.9	66.2	70.2	69.6	67.6	72.7			
5-year	55.5	56.0	59.2	60.3	60.3	60.3	63.3	59.2	62.1	64.7	60.8	64.5	65.1	67.4	64.2	66.8	67.6	66.3				
6-year	53.0	52.9	56.2	57.8	58.0	58.9	60.7	57.6	59.7	63.3	59.3	62.8	63.3	64.1	63.0	64.0	66.6					
7-year	51.0	50.7	53.1	55.9	56.4	57.9	58.0	56.3	56.7	61.7	57.8	60.3	61.3	61.4	61.3	61.9						
8-year	48.4	49.2	51.5	53.2	54.5	55.1	56.8	55.7	54.1	59.7	56.2	58.0	60.1	61.4	60.3							
9-year	46.8	46.9	49.7	51.0	52.5	53.1	55.8	55.7	52.1	58.6	53.4	56.9	58.1	59.9								
10-year	44.8	45.7	48.5	48.9	51.2	51.2	53.4	54.2	50.0	56.8	50.7	55.4	57.3									
11-year	43.0	44.2	47.0	46.6	49.7	50.5	50.8	52.2	49.2	55.2	49.6	53.2										
12-year	41.4	42.3	45.1	45.7	47.6	49.4	49.4	50.5	47.2	53.8	47.2											
13-year	39.9	40.2	43.5	44.1	46.3	47.1	48.5	48.8	46.7	52.3												
14-year	38.6	39.1	42.0	42.9	45.1	44.2	48.4	46.7	46.1													
15-year	37.0	37.2	40.7	42.0	44.5	43.4	47.2	45.9														
16-year	35.9	35.9	39.4	41.0	43.5	42.4	46.1															
17-year	34.9	35.0	38.4	39.8	42.4	40.9																
18-year	33.6	34.1	36.8	38.8	41.0																	
19-year	32.6	33.0	35.9	37.2																		
20-year	31.2	32.4	35.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 21.9  
Cancer of the Ovary (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	64.1	69.6	69.6	71.9	73.0	73.8	76.7	75.0	74.0	76.8	76.0	75.4	75.9	75.3	75.2	75.4	75.3	75.8	76.0	76.9	78.2	78.2
2-year	48.9	53.1	54.1	58.6	60.1	61.5	65.3	64.1	61.5	63.6	65.2	63.4	65.9	64.7	64.4	64.0	64.0	64.7	67.1	66.6	68.8	
3-year	42.2	45.8	46.4	49.8	51.1	52.9	56.6	55.1	52.8	54.5	55.8	54.3	58.3	56.4	55.8	55.5	55.7	56.2	57.8	58.6		
4-year	38.6	41.5	41.4	44.4	46.1	46.3	48.8	50.1	47.5	47.5	50.2	47.9	49.9	49.7	49.8	49.6	49.0	50.0	52.2			
5-year	36.6	38.8	38.1	40.8	42.2	42.2	44.2	45.3	42.8	43.0	45.7	42.7	44.3	44.3	44.4	45.3	44.3	46.2				
6-year	35.2	37.0	36.0	38.2	38.9	38.9	40.4	42.3	40.1	39.9	42.7	39.4	41.0	41.2	41.0	42.1	41.7					
7-year	33.9	36.1	34.7	36.7	36.9	37.3	38.1	40.6	38.1	37.3	40.1	37.4	38.3	39.3	39.1	40.1						
8-year	33.0	34.6	33.7	35.5	35.1	36.2	36.8	38.5	36.4	35.7	37.8	35.7	36.8	37.4	37.8							
9-year	32.4	33.7	33.0	34.4	33.6	35.4	35.4	36.8	34.9	34.3	36.0	34.8	35.4	35.7								
10-year	32.0	32.9	32.4	33.6	32.7	34.5	34.3	35.8	34.0	33.1	34.9	33.9	34.2									
11-year	31.6	32.4	32.0	32.8	31.9	33.7	33.1	35.0	32.6	32.3	34.2	33.1										
12-year	31.0	31.8	31.4	32.3	31.8	33.2	32.2	34.5	31.7	31.7	33.0											
13-year	30.7	31.2	30.8	31.9	31.4	32.7	31.7	33.2	31.1	31.1												
14-year	30.2	30.7	30.4	31.6	31.3	31.9	31.4	32.5	30.0													
15-year	29.6	30.6	30.2	31.1	30.8	31.4	31.4	31.9														
16-year	29.2	30.4	30.2	31.0	30.5	30.8	30.4															
17-year	28.9	29.9	30.0	30.6	30.3	30.6																
18-year	28.8	29.8	29.9	30.3	29.9																	
19-year	28.5	29.5	29.8	29.9																		
20-year	28.3	29.2	29.5																			

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 22.9  
Cancer of the Pancreas (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	14.2	15.9	17.1	18.5	17.8	19.1	20.0	19.6	22.2	21.9	23.9	25.1	22.7	23.1	26.9	25.9	27.9	29.9	29.7	30.4	31.2	34.6
2-year	5.9	6.3	6.8	8.6	8.3	9.3	9.9	8.7	10.5	10.9	11.4	11.8	11.3	11.9	12.9	13.0	13.9	15.0	15.7	16.6	15.9	
3-year	3.6	4.1	4.7	5.8	5.2	6.3	7.1	5.6	6.5	7.3	7.3	8.4	7.5	8.3	9.0	9.2	9.8	10.3	11.7	11.8		
4-year	3.0	3.3	3.8	4.8	4.0	4.8	5.5	4.5	5.6	6.0	6.1	6.7	5.7	6.4	7.2	7.9	8.3	8.4	9.7			
5-year	2.5	2.8	3.3	4.2	3.6	4.2	5.0	3.8	5.1	5.1	5.1	6.1	4.9	5.5	6.3	7.3	7.7	7.6				
6-year	2.3	2.5	2.9	4.0	3.2	3.8	4.5	3.7	4.6	4.6	4.7	5.6	4.5	5.0	5.7	6.7	7.0					
7-year	2.1	2.3	2.7	3.6	3.1	3.5	4.3	3.4	4.3	4.3	4.2	4.9	4.2	4.7	5.4	5.9						
8-year	1.9	2.1	2.5	3.4	2.7	3.4	4.1	3.1	4.0	3.8	3.9	4.7	4.0	4.3	5.0							
9-year	1.8	2.0	2.2	3.2	2.6	3.3	4.0	2.8	3.8	3.7	3.8	4.5	3.7	4.1								
10-year	1.8	1.9	2.2	3.0	2.5	3.2	3.9	2.7	3.6	3.6	3.5	4.4	3.4									
11-year	1.7	1.7	2.1	2.8	2.5	2.9	3.8	2.5	3.3	3.5	3.3	4.0										
12-year	1.7	1.7	2.1	2.7	2.3	2.8	3.6	2.4	3.2	3.1	3.1											
13-year	1.6	1.6	2.0	2.6	2.2	2.7	3.3	2.3	3.1	3.0												
14-year	1.6	1.6	1.9	2.5	1.9	2.7	3.1	1.9	3.1													
15-year	1.5	1.5	1.8	2.4	1.8	2.7	3.0	1.9														
16-year	1.5	1.4	1.7	2.2	1.7	2.2	2.9															
17-year	1.4	1.4	1.7	2.2	1.4	1.9																
18-year	1.3	1.3	1.7	2.2	1.4																	
19-year	1.3	1.3	1.6	2.1																		
20-year	1.2	1.3	1.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 22.10  
Cancer of the Pancreas (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	14.2	15.1	16.8	17.9	16.9	20.0	21.3	19.4	22.7	22.0	23.4	24.9	24.2	25.2	26.0	27.3	28.2	31.4	29.5	30.0	32.4	34.6
2-year	5.8	5.9	6.2	8.4	7.3	10.9	9.9	9.2	9.8	11.4	12.1	11.1	11.5	12.5	11.9	13.5	13.7	16.0	16.6	16.3	17.5	
3-year	3.4	3.8	4.4	5.8	4.1	7.1	7.0	5.6	5.9	7.1	8.0	8.1	7.5	8.1	7.8	9.6	9.1	11.2	12.6	12.0		
4-year	3.0	3.0	3.2	4.6	3.5	5.8	5.5	4.6	5.5	5.9	6.4	6.8	5.5	5.8	5.6	8.0	7.9	9.5	10.7			
5-year	2.6	2.5	2.9	4.0	3.0	5.1	4.7	4.0	4.9	5.2	5.5	6.0	4.5	4.9	5.1	7.4	7.3	8.7				
6-year	2.4	2.2	2.4	3.8	2.7	4.7	3.9	3.8	4.0	4.9	5.1	5.2	4.1	4.3	4.6	6.8	6.4					
7-year	2.3	1.9	2.3	3.4	2.7	4.2	3.4	3.5	3.9	4.5	4.6	4.7	3.8	3.9	4.2	5.9						
8-year	2.0	1.7	2.1	3.1	2.4	4.2	3.4	3.3	3.8	3.9	4.2	4.3	3.7	3.5	3.9							
9-year	1.9	1.6	1.8	3.0	2.2	4.0	3.3	2.9	3.6	3.7	4.1	4.2	3.4	3.4								
10-year	1.8	1.5	1.7	2.7	2.1	3.8	3.2	2.9	3.6	3.5	3.9	4.1	2.7									
11-year	1.7	1.5	1.7	2.7	2.0	3.2	2.9	2.9	3.2	3.5	3.7	3.5										
12-year	1.6	1.5	1.7	2.6	1.8	3.0	2.8	2.6	3.1	2.9	3.4											
13-year	1.6	1.4	1.5	2.5	1.7	3.0	2.6	2.6	3.0	2.7												
14-year	1.6	1.4	1.5	2.4	1.2	2.9	2.4	2.4	3.0													
15-year	1.6	1.3	1.3	2.3	1.2	2.8	2.2	2.4														
16-year	1.6	1.3	1.3	2.1	1.2	2.0	1.9															
17-year	1.4	1.3	1.3	2.1	0.8	1.7																
18-year	1.3	1.3	1.2	2.1	0.7																	
19-year	1.2	1.3	1.2	2.1																		
20-year	1.1	1.2	1.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 22.11  
Cancer of the Pancreas (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	14.2	16.8	17.4	19.2	18.6	18.3	18.9	19.9	21.7	21.7	24.3	25.3	21.3	20.9	27.9	24.7	27.6	28.5	29.9	30.8	29.8	34.6
2-year	5.9	6.6	7.3	8.7	9.1	7.9	9.9	8.3	11.1	10.5	10.8	12.5	11.2	11.3	14.0	12.6	14.1	14.1	14.9	16.9	14.2	
3-year	3.8	4.4	5.1	5.8	6.2	5.5	7.2	5.7	7.1	7.6	6.7	8.6	7.5	8.5	10.1	8.8	10.4	9.5	10.7	11.6		
4-year	3.0	3.6	4.3	4.9	4.4	3.9	5.5	4.3	5.8	6.2	5.8	6.6	5.9	7.0	8.8	7.8	8.8	7.3	8.7			
5-year	2.4	3.2	3.7	4.4	4.2	3.4	5.2	3.7	5.2	5.0	4.6	6.2	5.3	6.1	7.5	7.3	8.1	6.4				
6-year	2.3	2.8	3.4	4.1	3.7	3.0	4.9	3.7	5.1	4.3	4.3	6.0	4.8	5.7	6.9	6.6	7.6					
7-year	2.0	2.7	3.1	3.8	3.4	2.8	4.9	3.4	4.7	3.9	3.7	5.1	4.5	5.4	6.6	5.9						
8-year	1.8	2.5	2.8	3.7	3.0	2.6	4.9	2.8	4.1	3.7	3.5	5.0	4.2	5.1	6.1							
9-year	1.8	2.3	2.7	3.4	3.0	2.5	4.6	2.5	3.9	3.6	3.4	4.8	4.0	4.9								
10-year	1.7	2.2	2.6	3.2	2.9	2.5	4.6	2.4	3.7	3.5	3.0	4.6	4.0									
11-year	1.7	2.0	2.5	2.9	2.9	2.5	4.6	2.1	3.4	3.5	2.9	4.4										
12-year	1.7	1.9	2.5	2.7	2.8	2.5	4.3	2.1	3.2	3.4	2.8											
13-year	1.6	1.8	2.4	2.7	2.6	2.3	3.9	1.9	3.2	3.3												
14-year	1.5	1.7	2.4	2.6	2.4	2.3	3.8	1.3	3.1													
15-year	1.3	1.6	2.3	2.3	2.2	2.3	3.7	1.3														
16-year	1.3	1.5	2.0	2.3	2.1	2.3	3.7															
17-year	1.3	1.5	2.0	2.3	2.0	2.1																
18-year	1.3	1.4	2.0	2.2	2.0																	
19-year	1.3	1.4	2.0	2.1																		
20-year	1.3	1.4	2.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 23.9  
Cancer of the Prostate (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	91.4	93.5	95.6	98.8	98.7	99.1	99.3	99.5	99.6	99.7	99.9	99.8	99.7	99.8	99.8	99.8	99.8	99.7	99.6	99.6	99.6	99.3
2-year	84.5	87.4	91.0	97.3	97.6	98.0	98.8	98.9	99.6	99.5	99.9	99.8	99.6	99.7	99.6	99.7	99.8	99.5	99.3	99.5	99.3	
3-year	78.3	81.5	86.9	96.0	96.9	97.4	98.4	98.5	99.5	99.1	99.9	99.7	99.4	99.7	99.5	99.7	99.8	99.2	99.2	99.5		
4-year	73.2	76.4	83.5	94.9	96.3	96.8	97.9	98.2	99.2	98.8	99.8	99.7	99.3	99.7	99.4	99.6	99.7	99.1	99.2			
5-year	68.8	72.0	80.5	93.8	95.7	96.4	97.4	98.1	99.2	98.8	99.8	99.7	99.1	99.7	99.1	99.5	99.7	99.1				
6-year	65.3	68.5	77.9	92.7	95.4	96.0	97.1	97.9	99.2	98.5	99.8	99.7	99.1	99.7	99.1	99.5	99.7					
7-year	61.8	65.0	75.4	91.6	94.9	95.3	97.1	97.6	99.0	98.4	99.8	99.7	99.0	99.7	99.1	99.5						
8-year	58.5	61.9	73.3	90.6	94.6	94.9	96.9	97.6	98.7	98.1	99.8	99.7	98.9	99.7	99.1							
9-year	55.8	59.7	71.4	89.4	94.2	94.4	96.6	97.0	98.4	98.1	99.8	99.7	98.4	99.5								
10-year	53.2	57.7	69.6	88.4	93.5	94.2	96.5	96.5	98.0	98.1	99.8	99.7	98.3									
11-year	50.6	55.5	67.8	87.5	92.7	93.9	96.2	96.1	97.8	97.2	99.8	99.7										
12-year	48.4	53.5	66.0	86.5	91.8	93.4	95.9	95.4	97.3	97.1	99.8											
13-year	46.5	51.7	64.4	85.9	90.8	92.9	95.1	95.2	97.0	96.6												
14-year	44.8	50.1	63.0	85.0	89.9	92.6	94.5	94.8	96.5													
15-year	43.6	48.7	61.5	84.1	89.1	91.9	94.4	94.8														
16-year	41.9	46.9	60.0	83.2	88.6	90.9	93.9															
17-year	40.1	45.8	59.4	82.3	87.6	90.4																
18-year	38.8	44.4	58.3	81.6	87.4																	
19-year	38.0	43.0	57.7	80.6																		
20-year	37.0	41.6	56.8																			
21-year	35.4	40.8	56.0																			
22-year	34.0	39.4	54.6																			
23-year	33.1	38.2	53.4																			
24-year	32.4	37.3	52.3																			
25-year	30.9	35.8																				
26-year	30.3	34.6																				
27-year	29.7	34.3																				
28-year	28.9	33.8																				
29-year	28.2	33.2																				
30-year	26.9																					

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 24.9  
Cancer of the Stomach (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	38.7	41.5	43.8	44.8	45.7	45.5	45.3	47.8	46.5	47.2	48.7	49.9	50.5	53.1	50.0	52.4	51.9	55.6	55.6	54.4	57.8	57.0
2-year	24.8	26.7	29.1	31.2	31.4	32.0	32.6	33.6	34.0	32.7	33.4	35.3	38.3	38.5	36.3	40.0	39.3	41.7	40.3	40.0	43.1	
3-year	19.7	21.0	23.4	25.1	26.5	26.8	26.3	28.3	27.7	26.9	29.0	30.2	33.4	33.0	31.6	34.5	33.5	36.4	35.8	34.8		
4-year	17.3	18.3	20.6	22.5	23.2	23.7	23.4	25.1	24.8	24.6	27.5	27.1	30.4	30.0	27.9	33.2	30.9	33.7	33.2			
5-year	15.6	16.6	19.3	20.8	21.9	22.2	21.8	22.7	23.0	22.9	26.4	26.1	27.9	28.2	25.8	31.2	28.8	31.6				
6-year	14.6	15.9	18.3	19.3	20.7	20.6	20.7	21.8	21.1	22.1	25.3	24.5	26.5	26.5	24.6	29.8	26.9					
7-year	14.0	15.1	17.6	18.4	19.5	20.0	20.0	21.0	20.0	21.2	24.3	23.8	25.7	25.3	23.8	28.8						
8-year	13.4	14.4	17.0	17.5	19.4	19.8	19.3	20.4	19.0	20.5	22.8	22.5	24.4	24.3	23.2							
9-year	13.1	14.1	16.5	16.9	19.0	19.3	19.3	19.5	18.6	19.9	22.3	21.6	24.0	23.5								
10-year	12.7	13.9	15.8	16.1	18.2	18.9	18.3	18.5	17.9	19.4	21.6	21.0	23.4									
11-year	12.3	13.4	15.3	15.8	17.7	17.7	17.7	18.5	17.2	18.4	21.1	20.0										
12-year	12.0	12.9	15.0	15.6	17.2	17.2	17.7	17.6	17.1	17.8	20.4											
13-year	11.6	12.9	14.9	15.2	16.7	16.1	17.7	16.8	15.7	17.3												
14-year	11.2	12.8	14.6	14.9	16.3	15.7	17.2	16.8	15.6													
15-year	10.9	12.3	14.3	14.6	16.3	15.5	17.2	16.8														
16-year	10.6	11.9	13.9	14.1	16.3	14.7	16.5															
17-year	10.2	11.6	13.8	13.8	16.3	14.0																
18-year	9.8	11.4	13.6	13.3	16.0																	
19-year	9.5	11.2	13.2	13.0																		
20-year	9.2	10.8	13.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 24.10  
Cancer of the Stomach (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	38.1	41.1	42.8	43.6	46.5	43.6	45.6	49.2	46.4	46.3	49.4	48.0	49.7	53.4	51.6	52.2	50.8	53.9	55.6	54.0	57.5	55.6
2-year	23.8	25.8	27.5	29.3	31.5	28.8	31.0	35.4	33.8	32.8	33.1	32.5	36.2	37.8	36.9	37.7	36.9	39.4	39.1	38.7	42.1	
3-year	18.5	20.0	21.4	23.3	25.9	23.7	24.9	29.5	27.4	27.2	28.6	27.0	31.4	30.9	31.4	33.0	31.5	33.0	33.9	33.5		
4-year	16.1	17.2	18.2	20.7	22.4	21.5	21.6	25.5	24.2	24.5	26.6	24.6	28.0	27.4	27.4	31.5	28.5	30.0	31.6			
5-year	14.5	15.4	16.7	18.8	20.8	20.2	19.9	23.1	22.2	22.3	25.7	23.5	25.3	26.1	25.2	29.8	26.6	28.6				
6-year	13.4	14.6	15.8	17.2	19.7	19.2	18.7	22.3	20.4	21.3	23.8	21.9	24.0	24.1	24.2	28.3	24.8					
7-year	12.6	13.9	15.0	16.2	18.7	18.8	17.8	21.2	18.7	20.1	22.9	21.0	23.5	23.2	23.5	27.2						
8-year	12.3	13.3	14.5	15.2	18.6	18.7	17.6	20.7	17.7	19.3	21.5	20.1	22.1	22.3	23.0							
9-year	12.2	13.0	13.9	14.5	18.5	18.0	17.4	19.9	16.8	18.1	21.4	19.7	21.9	21.5								
10-year	11.8	12.9	13.4	13.6	17.3	17.5	16.4	19.0	16.5	17.8	20.8	18.6	21.9									
11-year	11.4	12.5	12.8	13.4	17.1	15.7	15.8	19.0	15.9	16.5	20.5	17.6										
12-year	11.3	11.8	12.6	13.1	16.6	15.0	15.7	18.3	15.6	15.9	19.8											
13-year	11.0	11.8	12.6	12.7	16.0	14.8	15.7	17.5	14.6	15.3												
14-year	10.4	11.8	12.3	12.0	15.4	14.6	15.2	17.5	14.1													
15-year	10.0	11.3	11.9	11.4	15.4	14.6	15.1	17.5														
16-year	9.8	10.8	11.7	11.2	15.4	13.3	15.1															
17-year	9.5	10.4	11.5	11.1	15.3	12.0																
18-year	8.8	10.3	11.3	10.6	15.0																	
19-year	8.7	10.3	10.9	10.4																		
20-year	8.6	9.8	10.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 24.11  
Cancer of the Stomach (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	39.7	42.3	45.5	46.9	44.5	48.8	44.9	45.7	46.8	48.6	47.5	52.6	51.7	52.6	47.2	52.8	53.7	58.4	55.7	55.1	58.4	59.3
2-year	26.5	28.2	32.0	34.3	31.3	37.4	35.0	30.8	34.3	32.5	33.9	39.4	41.6	39.7	35.2	43.6	43.3	45.5	42.0	41.8	44.6	
3-year	21.5	22.7	26.7	28.1	27.5	31.7	28.4	26.5	28.2	26.4	29.7	35.0	36.6	36.2	31.8	36.8	36.7	42.0	38.5	36.6		
4-year	19.2	20.1	24.6	25.4	24.6	27.2	26.1	24.4	25.7	24.8	29.0	30.6	34.1	34.0	28.9	35.5	34.9	39.9	35.8			
5-year	17.5	18.7	23.6	24.1	23.6	25.7	24.9	22.1	24.3	23.7	27.6	30.0	31.9	31.6	26.7	33.4	32.6	36.7				
6-year	16.6	18.0	22.5	22.8	22.3	22.9	24.0	20.9	22.2	23.4	27.3	28.2	30.3	30.2	25.3	32.2	30.2					
7-year	16.2	17.2	21.8	22.0	21.0	21.7	23.2	20.7	21.9	22.8	26.5	27.9	29.0	28.4	24.1	31.1						
8-year	15.2	16.3	21.3	21.2	20.6	21.3	22.0	20.1	20.9	22.5	24.7	26.0	27.9	27.4	23.6							
9-year	14.5	15.9	20.8	20.7	19.7	21.3	22.0	18.8	20.9	22.5	23.6	24.3	27.0	26.9								
10-year	14.3	15.4	19.9	20.2	19.4	21.1	21.1	17.6	19.9	21.7	22.8	24.2	25.1									
11-year	13.7	15.0	19.5	19.7	18.8	21.0	20.6	17.4	18.9	21.3	22.0	23.6										
12-year	13.3	14.6	18.9	19.7	18.0	20.7	20.6	16.7	18.8	20.7	21.4											
13-year	12.6	14.5	18.7	19.3	17.7	18.0	20.6	15.6	17.4	20.6												
14-year	12.4	14.4	18.4	19.3	17.6	17.5	20.2	15.5	17.4													
15-year	12.2	13.9	18.1	19.3	17.6	16.5	20.2	15.5														
16-year	11.7	13.6	17.8	18.8	17.6	16.4	18.6															
17-year	11.5	13.4	17.5	18.3	17.6	16.4																
18-year	11.4	13.2	17.4	17.6	17.6																	
19-year	10.9	12.8	17.1	17.3																		
20-year	10.2	12.4	16.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 25.9  
Cancer of the Testis (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	93.2	95.8	98.0	97.7	98.1	97.6	97.4	97.9	96.9	97.9	98.5	98.2	98.4	97.9	98.1	98.9	98.9	98.7	98.6	98.1	97.6	99.0
2-year	88.5	92.6	96.2	96.4	97.4	96.4	95.7	96.6	96.3	96.6	97.4	97.1	96.9	96.4	97.3	98.4	97.5	97.2	97.5	97.4	97.4	
3-year	86.5	92.0	95.5	95.7	96.4	95.8	95.1	96.2	95.7	95.9	96.9	96.9	96.6	95.7	97.1	98.2	96.8	97.1	97.3	97.4		
4-year	85.6	91.5	95.0	95.7	96.3	95.8	94.8	96.1	95.6	95.9	96.8	96.7	96.5	95.3	96.8	98.0	96.5	96.7	97.2			
5-year	85.0	91.0	94.7	95.7	96.3	95.8	94.8	95.8	95.6	95.9	96.6	96.3	96.1	95.2	96.8	98.0	95.5	96.7				
6-year	84.7	90.9	94.5	95.5	96.3	95.8	94.7	95.6	95.5	95.9	96.1	96.1	96.1	95.2	96.4	97.8	94.9					
7-year	84.6	90.7	94.3	95.5	96.3	95.8	94.7	95.4	95.5	95.9	96.1	96.1	96.1	95.2	96.3	97.4						
8-year	84.5	90.5	94.1	95.0	96.3	95.8	94.7	95.4	95.4	95.9	96.1	96.0	96.1	95.2	96.2							
9-year	84.5	90.1	94.0	94.9	96.2	95.8	94.7	95.4	95.2	95.9	96.1	95.7	96.1	95.2								
10-year	83.7	89.9	93.8	94.9	96.1	95.8	94.7	94.7	95.2	95.9	96.1	95.5	96.1									
11-year	83.2	89.7	93.6	94.8	96.0	95.8	94.7	94.2	95.1	95.9	96.1	95.1										
12-year	82.9	89.7	93.5	94.8	96.0	95.8	94.7	94.1	95.1	95.9	96.1											
13-year	82.5	89.2	93.2	94.8	95.9	95.8	94.7	94.1	95.1	95.9												
14-year	82.0	88.8	93.1	94.8	95.7	95.8	94.7	93.9	95.1													
15-year	81.7	88.4	93.1	94.7	95.7	95.8	94.7	93.9														
16-year	81.2	88.0	92.9	94.6	95.7	95.8	94.5															
17-year	80.6	87.6	92.7	94.3	95.7	95.8																
18-year	80.0	87.4	92.6	94.3	95.7																	
19-year	79.5	87.2	92.5	94.2																		
20-year	79.3	86.8	92.3																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 26.9  
Cancer of the Thyroid (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Survival Time	Year of Diagnosis																					
	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
1-year	94.9	95.1	95.9	96.2	96.7	96.8	96.4	97.7	97.1	97.7	97.6	97.1	97.9	98.3	97.7	98.5	98.5	98.3	98.8	98.9	98.7	98.8
2-year	93.5	94.5	95.2	95.7	96.1	96.6	96.2	97.1	97.0	97.1	97.4	97.1	97.8	97.9	97.3	98.4	98.1	98.2	98.7	98.5	98.6	
3-year	92.9	93.7	94.8	95.3	96.0	96.0	96.2	96.9	97.0	97.0	97.0	97.1	97.6	97.9	97.3	98.3	98.0	98.2	98.7	98.5		
4-year	92.5	93.4	94.3	95.0	95.9	95.4	95.6	96.3	97.0	97.0	97.0	97.1	97.4	97.7	97.3	98.3	97.9	97.9	98.7			
5-year	92.1	93.3	94.1	94.6	95.7	95.0	95.3	96.2	96.8	96.3	96.2	97.1	97.3	97.3	97.3	98.2	97.9	97.8				
6-year	91.6	93.1	93.8	94.3	95.7	94.8	95.2	95.8	96.3	96.3	96.2	96.7	96.9	97.2	97.3	98.2	97.9					
7-year	91.4	92.7	93.4	94.1	95.6	94.5	95.2	95.8	96.1	96.1	96.1	96.5	96.7	96.8	97.3	98.1						
8-year	91.1	92.6	93.3	94.1	95.5	94.2	95.1	95.8	95.9	95.9	95.9	96.3	96.7	96.7	97.3							
9-year	90.7	92.3	93.1	93.9	95.5	93.7	94.9	95.8	95.5	95.9	95.3	96.3	96.7	96.7								
10-year	90.5	92.0	92.8	93.5	95.1	93.7	94.9	95.8	95.3	95.8	95.3	96.3	96.7									
11-year	90.3	91.7	92.7	93.3	95.0	93.3	94.9	95.8	94.9	95.8	95.3	96.0										
12-year	90.3	91.4	92.6	93.0	95.0	93.0	94.9	95.8	94.6	95.8	95.3											
13-year	90.0	91.2	92.4	92.9	95.0	92.8	94.9	95.0	94.6	95.8												
14-year	89.9	91.1	92.4	92.6	95.0	92.6	94.9	94.5	94.4													
15-year	89.7	90.7	92.3	92.3	94.2	92.4	94.9	94.0														
16-year	89.6	90.6	92.3	92.1	93.6	92.4	94.9															
17-year	89.5	90.6	92.2	92.1	93.6	92.3																
18-year	89.3	90.4	92.1	92.1	93.6																	
19-year	89.2	90.4	91.8	92.1																		
20-year	89.2	90.4	91.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).



Table 26.10  
Cancer of the Thyroid (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	94.6	92.5	94.8	94.6	93.3	93.7	91.8	97.2	96.5	96.4	96.1	95.1	95.6	96.7	97.0	96.4	97.2	96.8	98.3	97.8	97.3	97.9
2-year	92.5	92.0	93.7	93.2	91.8	93.4	90.9	95.4	96.2	95.1	95.4	94.9	95.3	95.1	95.5	96.1	96.5	96.1	98.2	96.3	96.9	
3-year	91.5	90.8	93.5	92.4	91.6	92.2	90.9	94.7	96.2	95.1	94.2	94.9	94.2	94.8	95.5	96.1	96.5	96.1	98.2	96.0		
4-year	90.5	90.4	92.1	91.9	91.4	91.7	89.5	93.6	96.2	95.1	93.6	94.6	93.5	94.3	95.5	96.1	96.4	95.7	98.2			
5-year	89.9	90.2	91.6	91.0	91.1	89.9	88.2	93.6	96.2	93.9	92.3	94.3	93.2	94.0	95.5	95.7	96.2	95.2				
6-year	89.6	89.8	91.1	90.6	90.2	89.9	88.0	93.5	95.8	93.9	91.9	93.8	91.7	94.0	95.5	95.7	96.2					
7-year	89.4	89.3	90.0	90.4	88.7	89.5	88.0	93.3	95.4	93.5	91.9	92.4	91.7	92.8	95.5	95.3						
8-year	89.3	89.3	89.6	90.1	88.6	88.5	87.8	93.3	95.2	93.5	91.0	91.5	91.7	92.5	95.2							
9-year	88.8	88.6	88.5	89.9	88.6	86.7	86.9	93.3	93.0	93.5	89.7	90.9	91.7	92.1								
10-year	88.3	87.8	88.4	89.7	87.3	86.5	86.9	93.2	92.6	93.5	89.5	90.9	91.7									
11-year	87.5	87.2	88.4	89.5	86.2	84.8	86.5	93.2	92.6	93.5	89.5	90.1										
12-year	87.5	86.4	88.3	88.7	86.0	84.2	86.5	93.0	92.6	93.5	89.5											
13-year	87.3	86.2	87.7	88.2	86.0	83.1	86.5	93.0	92.6	92.7												
14-year	87.3	86.2	87.7	87.8	85.7	82.8	86.5	93.0	92.6													
15-year	86.6	85.4	87.7	87.2	85.7	82.8	86.5	93.0														
16-year	86.5	85.3	87.7	86.9	85.7	82.8	86.5															
17-year	86.5	84.8	87.7	86.9	85.7	82.8																
18-year	86.5	84.5	87.7	86.5	85.7																	
19-year	86.5	84.5	87.6	86.4																		
20-year	86.5	84.5	87.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 26.11  
Cancer of the Thyroid (Invasive)  
SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	95.0	96.0	96.3	96.8	97.8	97.7	97.7	97.9	97.4	98.0	98.0	97.7	98.5	98.8	97.9	99.0	98.9	98.7	98.9	99.1	99.1	99.0
2-year	93.9	95.3	95.7	96.5	97.4	97.5	97.7	97.6	97.3	97.7	98.0	97.7	98.4	98.6	97.9	99.0	98.5	98.7	98.8	99.1	99.0	
3-year	93.3	94.7	95.2	96.3	97.3	97.1	97.7	97.5	97.3	97.5	97.7	97.7	98.4	98.6	97.9	98.9	98.5	98.7	98.8	99.1		
4-year	93.1	94.4	95.0	96.1	97.3	96.5	97.5	97.1	97.1	97.5	97.7	97.7	98.4	98.6	97.9	98.9	98.3	98.5	98.7			
5-year	92.7	94.3	94.9	95.9	97.2	96.4	97.4	96.9	96.8	97.0	97.3	97.7	98.4	98.3	97.9	98.9	98.3	98.5				
6-year	92.3	94.2	94.7	95.5	97.2	96.2	97.3	96.5	96.4	97.0	97.3	97.6	98.2	98.1	97.9	98.9	98.3					
7-year	92.1	93.8	94.5	95.3	97.2	95.9	97.3	96.5	96.2	97.0	97.3	97.6	98.0	98.0	97.9	98.9						
8-year	91.7	93.7	94.5	95.3	97.2	95.9	97.3	96.5	96.1	96.6	97.3	97.6	97.9	97.9	97.9							
9-year	91.3	93.6	94.5	95.2	97.2	95.8	97.3	96.5	96.1	96.6	97.0	97.6	97.8	97.9								
10-year	91.2	93.4	94.2	94.8	97.2	95.7	97.3	96.5	95.9	96.4	97.0	97.6	97.6									
11-year	91.2	93.1	94.0	94.5	97.2	95.7	97.3	96.5	95.6	96.4	97.0	97.6										
12-year	91.1	93.1	93.9	94.4	97.2	95.5	97.3	96.5	95.0	96.4	97.0											
13-year	90.9	92.9	93.9	94.4	97.2	95.5	97.3	95.5	94.7	96.4												
14-year	90.8	92.8	93.9	94.2	97.2	95.5	97.3	94.9	94.3													
15-year	90.7	92.4	93.8	94.0	96.5	95.0	97.3	94.2														
16-year	90.6	92.3	93.7	93.9	95.7	95.0	97.3															
17-year	90.4	92.3	93.5	93.9	95.7	94.9																
18-year	89.9	92.3	93.4	93.8	95.7																	
19-year	89.7	92.3	93.2	93.8																		
20-year	89.7	92.3	93.2																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 27.9  
Cancer of the Urinary Bladder (Invasive and *In Situ*)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	87.0	88.7	90.0	90.0	90.6	89.7	91.3	90.9	89.9	90.9	91.0	89.8	90.3	90.8	90.6	91.2	90.1	89.2	89.5	89.2	90.4	89.0
2-year	80.8	83.5	85.1	85.3	86.5	85.5	86.3	86.5	85.0	86.5	86.4	85.6	85.6	86.1	85.5	86.5	85.0	84.7	83.7	85.0	85.9	
3-year	77.6	80.4	82.2	82.8	84.0	83.4	83.1	83.4	82.3	83.6	84.5	83.5	83.4	83.6	82.6	83.8	82.0	81.8	81.3	81.6		
4-year	74.8	78.0	80.0	81.1	81.8	81.1	80.7	81.3	80.4	81.6	82.4	81.1	81.4	81.5	81.0	82.3	80.3	79.3	79.3			
5-year	73.0	76.1	78.1	79.5	81.1	79.6	78.5	79.2	78.1	80.3	81.5	79.9	79.7	80.0	80.0	80.7	78.9	77.5				
6-year	71.1	74.5	76.4	78.0	79.3	78.3	76.9	77.5	76.7	79.4	80.1	78.4	78.3	78.1	78.5	79.7	76.8					
7-year	68.9	72.9	74.9	76.3	77.4	77.3	75.8	76.3	75.7	77.8	78.3	77.3	77.1	75.9	77.7	77.7						
8-year	67.5	71.8	73.3	74.9	76.2	75.9	74.7	74.7	74.3	76.3	77.1	76.0	75.8	74.1	75.6							
9-year	65.8	70.0	72.1	73.5	74.6	74.1	73.2	73.4	73.1	75.4	75.9	74.6	74.8	72.9								
10-year	63.8	68.9	70.7	72.1	73.7	72.7	72.2	71.7	72.6	73.5	74.5	73.6	73.8									
11-year	62.1	67.5	69.6	70.9	73.0	71.6	71.2	70.8	71.5	71.6	73.7	72.2										
12-year	60.7	66.1	68.1	69.8	71.7	69.9	70.2	68.6	69.6	70.4	72.6											
13-year	59.7	65.1	66.8	69.0	69.3	68.8	69.8	67.8	68.1	69.0												
14-year	58.5	63.6	65.3	68.0	67.7	67.2	68.6	67.0	67.0													
15-year	57.1	62.2	64.0	66.3	67.1	67.1	67.1	66.5														
16-year	56.1	60.5	62.6	65.0	65.8	66.7	65.3															
17-year	55.1	59.6	61.7	63.8	64.2	65.4																
18-year	54.3	58.5	60.7	62.7	63.3																	
19-year	53.6	57.7	60.0	61.4																		
20-year	52.8	57.1	59.4																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 27.10  
Cancer of the Urinary Bladder (Invasive and *In Situ*)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	89.0	89.9	91.7	91.7	92.1	91.2	93.0	92.6	91.7	92.1	91.6	91.9	91.8	91.9	92.1	92.5	91.6	90.8	90.6	90.9	91.8	90.7
2-year	82.7	85.1	87.0	87.5	87.9	87.1	88.3	88.3	86.8	87.9	86.9	88.3	87.2	87.7	87.2	88.1	86.5	86.6	84.7	87.0	87.5	
3-year	79.5	82.0	84.2	85.1	85.5	84.9	85.1	84.7	84.2	84.6	85.2	86.1	84.8	85.2	84.3	85.3	83.2	83.8	82.1	83.6		
4-year	76.5	79.4	81.9	83.4	83.1	82.6	82.4	82.6	81.9	82.5	83.0	83.4	82.8	83.2	82.7	83.9	81.3	80.8	80.3			
5-year	74.3	77.4	80.1	81.7	82.9	80.9	79.9	80.3	79.3	81.0	82.3	82.0	80.9	82.0	82.0	82.5	79.8	78.9				
6-year	72.3	75.8	78.4	80.1	80.9	79.6	78.0	78.7	77.6	80.2	80.8	80.6	79.2	80.1	80.7	81.4	77.7					
7-year	70.0	74.4	76.5	78.2	79.2	78.4	76.7	77.8	76.6	78.3	78.5	79.7	77.7	77.5	79.8	79.0						
8-year	68.3	73.2	74.9	76.8	77.8	76.9	75.9	76.0	75.2	76.6	77.7	78.3	76.3	75.6	77.7							
9-year	66.4	71.4	73.7	75.3	75.6	75.5	74.3	74.8	74.4	75.2	76.9	76.7	75.1	74.4								
10-year	64.2	70.3	72.3	73.9	74.7	73.9	73.2	73.0	74.1	73.0	75.5	75.6	73.8									
11-year	62.2	68.9	71.2	72.7	73.9	72.6	72.3	72.1	73.3	70.9	74.6	73.9										
12-year	60.8	67.4	69.5	71.6	72.5	70.7	70.8	69.7	72.0	69.4	73.8											
13-year	59.6	66.4	68.3	70.8	70.6	69.6	69.9	68.8	70.6	67.7												
14-year	58.4	64.6	66.7	70.1	68.7	67.7	68.2	68.3	69.6													
15-year	57.1	63.1	65.3	68.4	68.0	67.4	66.4	67.6														
16-year	55.8	61.2	63.8	67.1	66.1	67.1	64.4															
17-year	54.6	60.3	63.1	65.8	64.8	66.0																
18-year	53.6	59.3	61.8	64.9	64.0																	
19-year	52.8	58.6	61.2	63.5																		
20-year	52.0	58.1	60.7																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 27.11  
Cancer of the Urinary Bladder (Invasive and *In Situ*)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	81.4	85.0	85.0	85.0	86.7	85.3	86.3	85.9	84.8	87.5	89.3	83.6	85.8	87.5	86.2	87.1	85.2	84.2	86.1	83.9	85.8	83.5
2-year	75.2	79.0	79.7	79.2	82.4	80.8	80.5	81.2	80.1	82.3	85.0	77.9	81.1	81.3	80.6	81.8	79.9	79.1	80.9	79.0	80.7	
3-year	72.6	75.9	76.4	76.1	79.8	78.9	77.2	79.3	77.0	80.6	82.3	76.1	79.3	78.8	77.5	79.1	77.9	75.8	78.7	75.3		
4-year	70.2	73.7	74.4	74.7	78.2	76.9	75.6	77.6	75.8	78.8	80.3	74.5	77.6	76.4	76.0	77.2	77.0	74.2	76.2			
5-year	69.2	72.1	72.3	73.0	76.0	75.7	74.5	75.9	74.7	78.3	78.9	73.6	76.0	74.1	74.3	75.3	75.8	73.1				
6-year	67.7	70.5	70.8	71.7	74.8	74.5	73.7	73.6	74.0	76.5	77.9	71.9	75.3	72.0	72.0	74.2	73.9					
7-year	65.9	68.8	70.0	70.6	72.6	74.0	72.9	72.0	72.8	76.1	77.5	69.8	75.1	70.9	71.3	73.9						
8-year	65.2	67.6	68.6	69.4	71.9	72.9	71.2	71.1	71.9	75.2	75.4	69.5	74.4	69.7	69.5							
9-year	64.1	66.0	67.4	68.3	71.4	70.0	70.1	69.1	69.2	75.2	72.8	68.6	73.9	68.2								
10-year	62.5	64.8	66.1	66.7	70.7	69.3	68.6	67.5	68.2	74.4	71.5	67.8	73.3									
11-year	61.5	63.3	64.8	65.6	70.0	68.8	67.9	67.2	65.6	73.5	71.1	67.0										
12-year	60.1	62.5	63.8	64.6	69.3	67.8	67.9	65.3	62.9	73.0	69.3											
13-year	59.6	61.3	62.5	63.7	65.6	66.6	67.9	64.6	61.2	72.9												
14-year	58.1	60.3	61.2	62.0	64.7	65.8	67.9	63.0	59.9													
15-year	56.8	59.4	60.2	60.2	64.3	65.8	67.9	62.8														
16-year	56.7	58.3	59.0	58.9	64.1	65.1	67.8															
17-year	55.8	57.4	57.7	57.9	62.3	63.5																
18-year	55.4	56.1	57.2	56.4	61.4																	
19-year	55.3	54.7	56.4	55.5																		
20-year	54.3	54.0	55.6																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 28.10  
All Cancer Sites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Ages 0-14

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	80.5	84.5	86.7	89.6	90.4	92.7	90.9	90.7	91.1	92.5	92.0	91.5	93.3	92.7	92.5	94.0	92.3	92.5	92.2	93.0	95.1	93.6
2-year	70.9	75.5	78.4	83.0	84.6	86.5	84.7	84.3	85.3	86.0	86.9	87.3	89.2	88.3	87.9	89.3	87.8	88.1	86.6	89.5	90.9	
3-year	65.2	70.7	74.3	79.7	81.0	83.7	82.3	81.5	82.9	83.2	84.1	84.0	86.1	85.4	84.9	87.8	86.2	86.1	84.0	86.8		
4-year	62.0	67.5	71.9	77.6	79.0	80.9	80.5	78.8	81.4	81.6	82.5	82.4	85.2	83.9	83.4	86.4	84.7	84.2	83.1			
5-year	59.8	65.9	70.7	76.4	77.4	80.5	79.3	78.0	79.6	80.7	81.9	81.4	84.1	83.1	82.1	85.7	83.5	83.3				
6-year	58.1	64.7	69.7	75.8	76.4	79.8	78.4	76.6	79.1	79.5	81.1	80.6	83.7	82.8	81.1	85.0	82.1					
7-year	57.1	63.8	68.7	75.2	75.9	79.2	78.0	76.1	78.4	79.0	80.1	80.1	83.1	82.0	80.6	84.6						
8-year	56.4	63.1	68.2	74.7	75.0	78.7	76.9	75.7	78.1	78.3	80.0	79.5	82.4	81.4	79.9							
9-year	56.0	62.6	67.8	74.3	74.7	78.4	76.7	75.1	77.6	78.3	79.5	79.3	81.7	81.1								
10-year	55.8	62.1	67.4	74.1	74.6	78.1	76.1	74.8	77.2	78.0	79.4	78.8	81.6									
11-year	55.4	61.8	67.1	73.8	74.3	78.0	75.9	74.3	76.8	77.7	79.1	78.0										
12-year	55.1	61.2	66.8	73.6	74.1	77.9	75.6	74.1	76.7	77.7	79.0											
13-year	54.8	60.9	66.6	73.3	74.0	77.8	75.4	73.6	76.4	77.2												
14-year	54.5	60.6	66.2	73.1	74.0	77.6	75.3	73.6	76.4													
15-year	54.3	60.3	66.0	72.8	73.9	77.4	75.2	73.5														
16-year	53.9	60.1	65.8	72.5	73.2	77.4	75.0															
17-year	53.6	59.8	65.6	72.3	72.9	77.2																
18-year	53.3	59.5	65.4	72.1	72.8																	
19-year	53.0	59.3	65.3	71.9																		
20-year	52.9	59.1	65.0																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table 28.11  
All Cancer Sites (Invasive)

SEER<sup>a</sup> Relative Survival (Percent)  
By Year of Diagnosis

All Races, Males and Females

Ages 0-19

Year of Diagnosis

	1975- 1979	1980- 1984	1985- 1989	1990- 1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012
Survival Time																						
1-year	82.5	85.7	88.2	90.2	90.1	93.1	91.4	91.7	90.8	91.2	92.3	92.3	93.5	92.4	92.8	94.1	93.1	93.8	93.6	93.0	95.3	94.6
2-year	73.0	77.2	80.3	83.3	84.6	87.5	85.1	85.3	85.8	84.3	87.3	87.3	89.1	88.0	88.6	89.0	88.4	89.3	88.5	89.4	91.3	
3-year	67.9	72.4	76.5	80.0	81.3	85.1	82.0	82.5	83.0	81.9	84.3	84.1	86.2	84.7	86.0	87.3	86.6	87.1	86.0	86.8		
4-year	64.9	69.5	74.0	78.0	79.8	82.4	80.4	79.9	81.3	80.3	82.6	82.2	85.2	83.6	84.5	85.8	84.8	85.1	85.0			
5-year	62.8	67.8	72.9	76.7	78.4	81.8	78.8	78.8	79.8	79.2	81.8	81.1	84.1	82.4	83.3	85.0	83.5	83.8				
6-year	61.1	66.5	71.9	76.0	77.4	81.2	77.7	77.7	79.4	78.4	81.2	80.2	83.7	82.1	82.0	83.9	82.2					
7-year	60.3	65.7	71.1	75.4	76.9	80.8	77.5	77.4	78.9	77.7	80.2	79.8	83.1	81.4	81.6	83.4						
8-year	59.5	64.9	70.5	74.9	76.0	80.2	76.7	77.0	78.7	77.1	80.0	79.0	82.4	80.9	80.8							
9-year	59.0	64.3	70.0	74.5	75.7	79.8	76.5	76.5	78.3	77.0	79.6	78.7	82.0	80.4								
10-year	58.6	63.8	69.6	74.3	75.5	79.5	75.8	76.1	78.0	76.7	79.5	78.3	81.8									
11-year	58.3	63.5	69.3	74.0	75.4	79.3	75.7	75.7	77.7	76.6	79.3	77.7										
12-year	57.9	63.0	69.1	73.8	75.1	79.3	75.5	75.3	77.5	76.3	79.1											
13-year	57.7	62.7	68.8	73.4	75.0	79.1	75.2	74.9	77.2	75.9												
14-year	57.5	62.3	68.3	73.2	75.0	79.0	75.1	74.8	77.2													
15-year	57.2	62.1	68.1	73.0	74.9	78.8	74.9	74.8														
16-year	56.9	61.6	67.8	72.7	74.3	78.7	74.6															
17-year	56.6	61.4	67.6	72.5	74.1	78.4																
18-year	56.3	61.2	67.4	72.3	74.0																	
19-year	56.1	60.9	67.1	72.0																		
20-year	55.8	60.6	66.8																			

<sup>a</sup> Based on the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).